<PAGE>
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A
[X] Quarterly report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934 for the quarterly period ended
September 30, 1999
[ ] Transition Report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934 for the transition period from
to .
-------------------------- ------------------------
Commission file number 0-23862
Fonix Corporation
(Exact name of registrant as specified in its charter)
Delaware 22-2994719
(State of Incorporation) (I.R.S. Employer Identification No.)
60 East South Temple Street, Suite 1225
Salt Lake City, UT 84111
(Address of principal executive offices and zip code)
(801) 328-0161
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant: (1) has filed all reports
required to be filed by Section 13 or Section 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes X or No
As of December 29, 1999, 124,337,123 shares of the issuer's Class A Common Stock
and 1,985,000 shares of Class B Non-Voting Common Stock, par value $.0001 per
share, were issued and outstanding.
<PAGE>
This Amendment No. 1 to the Quarterly Report on Form 10-Q of Fonix
Corporation is submitted to amend the following Items, which originally were
submitted as part of the Quarterly Report filed with the Securities and Exchange
Commission as of November 22, 1999:
Part I
Item 1. Financial Statements 3
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations 20
Part II
Item 1. Legal Proceedings 33
Pursuant to SEC Rule 12b-15, the foregoing Items, as amended hereby, are set
forth below in their entirety.
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements.
Interim unaudited condensed consolidated financial statements as
required by Rule 10-01 of Regulation S-X follow immediately.
Table of Contents
Interim unaudited condensed consolidated financial statements for the period
ended September 30, 1999
Condensed Consolidated Balance Sheets (Unaudited) 3
Condensed Consolidated Statements of Operations (Unaudited) 4
Condensed Consolidated Statements of Cash Flows (Unaudited) -
Increase (Decrease) in Cash and Cash Equivalents 5
Condensed Consolidated Statements of Cash Flows (Unaudited) (Continued) 6
Notes to Condensed Consolidated Financial Statements (Unaudited) 7
2
<PAGE>
Fonix Corporation and Subsidiaries
[A Development Stage Company]
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
<TABLE>
<CAPTION>
ASSETS
September 30, December 31,
1999 1998
--------------- ------------
<S> <C> <C>
Current assets:
Cash and cash equivalents $ 2,048,257 $ 20,045,539
Notes receivable - 245,000
Accounts receivable, net of allowance for doubtful accounts of
$74,000 and $8,000, respectively 331,451 219,908
Prepaid expenses 7,901 51,866
Inventory 1,894 4,804
Interest and other receivables 20,712 3,722
Employee advances - 67,231
--------------- ------------
Total current assets 2,410,215 20,638,070
Cash held in escrow 2,500,000 -
Property and equipment, net of accumulated depreciation of $1,740,234
and $1,168,023, respectively 1,347,061 2,145,031
Intangible assets, net of accumulated amortization of $3,757,780 and
$1,770,668, respectively 16,034,270 19,437,290
Other assets 106,536 107,945
Net long term assets of discontinued operations - 19,584,455
--------------- ------------
Total assets $ 22,398,082 $ 61,912,791
=============== ============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Bank overdraft $ - $ 138,034
Revolving notes payable - 20,038,193
Notes payable - related parties 77,625 8,491,880
Notes payable - other - 560,000
Capital lease obligation 5,180 52,225
Accounts payable 1,756,032 3,536,074
Accrued liabilities 2,659,267 981,774
Accrued liabilities - related parties 1,998,590 900,004
Income taxes payable 250,000 -
Deferred revenues 63,722 20,000
Net current liabilities of discontinued operations - 598,861
--------------- ------------
Total current liabilities 6,810,416 35,317,045
Series C 5% convertible debentures 3,971,107 -
--------------- ------------
Total liabilities 10,781,523 35,317,045
--------------- ------------
Common stock and related repricing rights subject to redemption; 1,801,802 shares and
repricing rights outstanding (aggregate redemption value of $2,500,000) 1,830,000 1,830,000
--------------- ------------
Commitments and contingencies (Notes 8, 9, and 15)
Stockholders' equity:
Preferred stock, $.0001 par value; 20,000,000 shares authorized; Series A,
convertible; 166,667 shares outstanding
(aggregate liquidation preference of $6,055,012) 500,000 500,000
Series D, 4% cumulative convertible; 876,667 and 958,334 shares
outstanding, respectively
(aggregate liquidation preference of $18,299,103) 20,705,530 22,200,936
Series E, 4% cumulative convertible; 250,000 shares outstanding in 1998 - 3,257,886
Common stock, $.0001 par value; 100,000,000 shares authorized;
83,750,179 and 64,324,480 shares outstanding, respectively 8,375 6,432
Additional paid-in capital 99,217,980 88,517,711
Outstanding warrants 3,585,399 3,323,258
Deferred consulting expense - (106,700)
Deficit accumulated during the development stage (114,230,725) (92,933,777)
--------------- ------------
Total stockholders' equity 9,786,559 24,765,746
--------------- ------------
Total liabilities and stockholders' equity $ 22,398,082 $61,912,791
=============== ============
</TABLE>
See accompanying notes to condensed consolidated financial statements.
3
<PAGE>
Fonix Corporation and Subsidiaries
[A Development Stage Company]
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
<TABLE>
<CAPTION>
October 1,
1993
Three Months Ended Nine Months Ended (Inception) to
September 30, September 30, September 30,
-------------------------- --------------------------
1999 1998 1999 1998 1999
------------ ------------- ------------- ------------ -------------
<S> <C> <C> <C> <C> <C>
Revenues $ 65,707 $ 95,500 $ 351,083 $ 2,567,785 $ 2,955,807
Cost of revenues 7,919 7,372 21,159 31,561 56,599
------------ ------------- ------------- ------------- -------------
Gross margin 57,788 88,128 329,924 2,536,224 2,899,208
------------ ------------- ------------- ------------- -------------
Expenses:
Selling, general and administrative 2,864,400 2,672,252 7,537,577 6,112,765 38,601,890
Product development and research 1,906,968 4,296,938 6,278,318 9,958,433 37,276,215
Amortization of goodwill and purchased core
technology 630,609 500,776 1,962,443 1,100,336 3,674,710
Purchased in-process research and development - - - 9,315,000 9,315,000
------------ ------------- ------------- ------------- -------------
Total expenses 5,401,977 7,469,966 15,778,338 26,486,534 88,867,815
------------ ------------- ------------- ------------- -------------
Loss from operations (5,344,189) (7,381,838) (15,448,414) (23,950,310) (85,968,607)
------------ ------------- ------------- ------------ -------------
Other income (expense):
Interest income 26,198 292,241 46,752 856,123 3,713,840
Interest expense (1,577,413) (365,902) (4,314,809) (960,803) (9,638,041)
Other expense (154,940) - (154,940) - (154,940)
Cancellation of common stock reset provision - (6,111,577) - (6,111,577) (6,111,577)
------------ ------------- ------------- ------------- -------------
Total other income (expense), net (1,706,155) (6,185,238) (4,422,997) (6,216,257) (12,190,718)
------------ ------------- ------------- ------------- -------------
Loss from continuing operations (7,050,344) (13,567,076) (19,871,411) (30,166,567) (98,159,325)
Discontinued operations:
Operating loss of HealthCare
Solutions Group (2,962,147) (5,026,049) (5,953,726) (5,026,049) (12,229,033)
Gain on disposal of HealthCare Solutions Group,
net of income taxes of $250,000 6,616,646 - 6,616,646 - 6,616,646
------------ ------------- ------------- ------------- -------------
Loss before extraordinary items (3,395,845) (18,593,125) (19,208,491) (35,192,616) (103,771,712)
Extraordinary items:
Loss on extinguishment of debt - - - - (881,864)
Gain on forgiveness of accounts payable and
accrued interest 372,061 - 372,061 - 402,609
------------ ------------- ------------- ------------- -------------
Net loss $(3,023,784) $(18,593,125) $(18,836,430) $ (35,192,616) $(104,250,967)
============ ============ =========== ============= =============
Basic and diluted net loss per common share $ (0.05) $ (0.39) $ (0.31) $ (0.75)
============ =========== =========== ===========
</TABLE>
See accompanying notes to condensed consolidated financial statements.
4
<PAGE>
Fonix Corporation and Subsidiaries
[A Development Stage Company]
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Increase (Decrease) in Cash and Cash Equivalents
<TABLE>
<CAPTION>
October 1,
1993
Nine Months Ended (Inception) to
September 30, September 30,
-------------------------------
1999 1998 1999
-------------- -------------- --------------
<S> <C> <C> <C>
Cash flows from operating activities:
Net loss $ (18,836,430) $(35,192,616) $(104,250,967)
Adjustments to reconcile net loss to net cash
used in operating activities:
Issuance of common stock for services 100,000 - 5,587,554
Issuance of common stock for patent - 100,807 100,807
Non-cash expense related to issuance of notes payable,
debentures, warrants, preferred and common stock 2,270,000 6,111,577 12,348,914
Non-cash compensation expense related to issuance
of stock options 119,240 133,375 2,615,540
Non-cash expense related to issuance of notes payable
and accrued expense for services - 857,000 857,000
Non-cash exchange of notes receivable for services - 150,000 150,000
Non-cash portion of purchased in-process research and
development - 12,635,768 13,136,000
Loss on disposal of property and equipment 154,940 (88) 154,940
Gain on sale of HealthCare Solutions Group (6,616,646) - (6,615,365)
Depreciation and amortization 4,423,595 1,802,814 8,199,049
Extraordinary loss on extinguishment of debt - - 881,864
Extraordinary gain on forgiveness of accounts payable and
accrued interest (372,061) - (402,609)
Changes in assets and liabilities, net of effects of
acquisitions and disposition:
Accounts receivable (391,982) (183,418) (540,480)
Employee advances (755) - (67,986)
Interest and other receivables (4,436) (74,009) (9,919)
Inventory (7,509) (8,358) (27,730)
Prepaid assets 40,465 (100,281) (7,001)
Other assets 270 (80,212) (119,575)
Accounts payable (1,558,666) 2,381,610 3,455,070
Accrued liabilities 1,632,083 482,568 2,273,872
Accrued liabilities - related party 1,249,271 (370,966) 1,397,030
Deferred revenues 568,115 2,126 649,381
-------------- ------------- --------------
Net cash used in operating activities (17,230,506) (11,352,303) (60,234,611)
-------------- ------------- --------------
Cash flows from investing activities, net of effects
of acquisitions and disposition:
Proceeds from sale of HealthCare Solutions Group 21,305,982 - 21,305,982
Acquisition of subsidiaries, net of cash acquired - (14,738,495) (15,323,173)
Proceeds from sale of property and equipment 50,000 500 50,000
Purchase of property and equipment (99,089) (1,240,540) (3,435,559)
Investment in intangible assets - (94,789) (164,460)
Issuance of notes receivable - (1,322,139) (3,228,600)
Payments received on notes receivable 245,000 - 2,128,600
-------------- ------------- --------------
Net cash provided by (used in) investing activities 21,501,893 (17,395,463) 1,332,790
-------------- ------------- --------------
Cash flows from financing activities:
Bank overdraft (138,034) 178,757 -
Net proceeds (payments) from revolving note payable (20,038,193) 1,422,264 (49,250)
Net proceeds (payments) from revolving note payable -
related parties (7,895,178) (514,296) (7,813,537)
Net proceeds from other notes payable 6,953,760 100,000 9,865,427
Payments on other notes payable (7,788,000) (49,250) (9,567,806)
Principal payments on capital lease obligations (55,504) (36,284) (148,210)
Proceeds from issuance of convertible debentures, net 6,254,240 - 9,439,240
Proceeds from sale of warrants 438,240 322,928 1,511,168
Proceeds from sale of common stock, net - 17,471,155 38,175,700
Proceeds from sale of preferred stock, net - 9,403,846 17,707,346
Proceeds from sale of common stock and related repricing rights
subject to redemption, net - - 1,830,000
-------------- ------------- --------------
Net cash (used in) provided by financing activities (22,268,669) 28,299,120 60,950,078
-------------- ------------- --------------
Net (decrease) increase in cash and cash equivalents (17,997,282) (448,646) 2,048,257
Cash and cash equivalents at beginning of period 20,045,539 20,501,676 -
-------------- ------------- --------------
Cash and cash equivalents at end of period $ 2,048,257 $ 20,053,030 $ 2,048,257
============== ============= ==============
</TABLE>
See accompanying notes to condensed consolidated financial statements.
5
<PAGE>
Fonix Corporation and Subsidiaries
[A Development Stage Company]
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)
(Unaudited)
<TABLE>
<CAPTION>
October 1,
1993
Nine Months Ended (Inception) to
September 30, September 30,
---------------------------
Supplemental disclosure of cash flow information: 1999 1998 1999
------------ ------------- ------------
<S> <C> <C> <C>
Cash paid during the period for interest $ 1,068,882 $ 747,629 $ 4,498,888
</TABLE>
Supplemental Schedule of Non-cash Investing and Financing Activities:
For the Nine Months Ended September 30, 1999:
The Company entered into capital lease obligations for equipment in the
amount of $57,332.
Advances to employees totaling $59,986 were applied as payments on a
related-party note payable.
A total of 143,230 shares of common stock previously pledged to a bank by
certain officers and directors of the Company as collateral for Company
credit card debt were sold by the bank and the proceeds were used to pay
the debt and the related accrued interest in full totaling $244,824.
A total of 100,000 shares of common stock previously pledged to a law firm
by certain officers and directors of the Company as collateral for legal
work were sold by the law firm and the proceeds were used to pay for legal
services totaling $72,335.
A total of 970,586 shares of common stock previously held by certain
shareholders and originally valued at $1,000,916 were returned to the
Company in settlement of litigation.
The Company issued 6,000,000 shares of common stock valued at $3,278,893 to
the guarantors of the Series C convertible debentures as indemnification
for the sale of their shares by the holders of the Series C convertible
debentures held as collateral for these debentures. The proceeds of
$3,278,893 received by the holders were used to pay liquidation damages and
retire Series C convertible debentures in the amounts of $750,000 and
$2,528,893, respectively.
Preferred stock dividends of $997,146 were recorded related to the
beneficial conversion features of Series D and Series E preferred stock.
Preferred stock dividends of $635,160 were accrued on Series D and Series E
preferred stock.
Dividends totaling $828,212 were accrued relating to the liquidation damage
provisions of Series D and Series E preferred stock and Series C
convertible debentures.
The Company issued 200,000 shares of common stock to an unrelated party for
consulting fees valued at $100,000.
A total of 131,667 shares of Series D preferred stock and related dividends
of $96,193 were converted into 8,468,129 shares of common stock.
A total of 135,072 shares of Series E preferred stock and related dividends
of $66,015 were converted into 5,729,156 shares of common stock.
In connection with the sale of HealthCare Solutions Group, $2,500,000 of
the sales price was placed into an escrow account.
A revolving note payable in the amount of $50,000 was paid by a former
employee and is included as an account payable.
Promissory notes held by certain shareholders were reduced by $414,991 in
settlement of litigation.
For the Nine Months Ended September 30, 1998:
The Company had a stock subscription receivable in the amount of $2,000,000
in connection with the issuance of 100,000 shares of Series E 4%
Convertible Preferred Stock that was consummated as of September 30, 1998.
This receivable was collected subsequent to period end.
Preferred Stock Dividends of $1,553,001 were recorded related to the
beneficial conversion features of Series D and Series E 4% Convertible
Preferred Stock.
The Company issued 1,390,476 shares of common stock and 608,334 shares of
Series D 4% Convertible Preferred Stock in connection with the cancellation
of existing reset provisions and costs associated with the issuance of
Series D 4% Convertible Preferred Stock.
Preferred Stock Dividends of $1,000,000 were recorded related to the
issuance of 1,390,476 common shares and 608,334 shares of Series D 4%
Convertible Preferred Stock in connection with the cancellation of existing
reset provisions.
Preferred Stock Dividends of $73,889 were accrued on Series D 4%
Convertible Preferred Stock.
The Company exchanged 150,000 shares of Series D 4% Convertible Preferred
Stock for 150,000 shares of Series E 4% Convertible Preferred Stock.
The Company issued 5,140,751 shares of common stock (having a market value
of $8,353,720) and notes payable of $4,747,339 in connection with the
acquisition of Articulate Systems, Inc.
Preferred Stock Dividends of $131,660 were recorded related to the
beneficial conversion features of Series B and Series C Convertible
Preferred Stock.
A total of 27,500 shares of Series B Preferred Stock and related dividends
of $8,531 were converted into 193,582 shares of common stock.
A total of 185,000 shares of Series C Preferred Stock and related dividends
of $123,129 were converted into 1,295,919 shares of common stock.
The Company issued 2,692,216 shares of common stock (having a market value
of $16,995,972) in connection with the acquisition of AcuVoice, Inc.
See accompanying notes to condensed consolidated financial statements.
6
<PAGE>
Fonix Corporation and Subsidiaries
(A Development Stage Company)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation - The accompanying unaudited condensed consolidated
financial statements of Fonix Corporation and subsidiaries (collectively, the
"Company" or "Fonix") have been prepared by the Company pursuant to the rules
and regulations of the Securities and Exchange Commission. Certain information
and footnote disclosures normally included in financial statements prepared in
accordance with generally accepted accounting principles have been condensed or
omitted pursuant to such rules and regulations, although the Company believes
that the following disclosures are adequate to make the information presented
not misleading.
These condensed consolidated financial statements reflect all adjustments
(consisting only of normal recurring adjustments) that, in the opinion of
management, are necessary to present fairly the financial position and results
of operations of the Company as of the balance sheet dates and for the periods
presented.
Operating results for the three and nine months ended September 30, 1999 are not
necessarily indicative of the results that may be expected for the year ending
December 31, 1999. The Company suggests that these condensed consolidated
financial statements be read in conjunction with the consolidated financial
statements and the notes thereto included in the Company's Annual Report on Form
10-K (Amendment No. 1) for the year ended December 31, 1998.
Recently Enacted Accounting Standards - In June 1998, the Financial Accounting
Standards Board issued Statement of Financial Accounting Standards ("SFAS") No.
133, "Accounting for Derivative Instruments and Hedging Activities." This
statement establishes accounting and reporting standards requiring that
derivative instruments be recorded in the balance sheet as either an asset or
liability measured at its fair value and that changes in the derivative's fair
value be recognized currently in earnings unless specific hedge accounting
criteria are met. SFAS No. 133 is effective for fiscal years beginning after
June 15, 2000. The adoption of this statement is not expected to have a material
effect on the Company's consolidated financial statements as the Company does
not currently hold any derivative or hedging instruments.
Reclassifications - Certain reclassifications have been made in the prior period
condensed consolidated financial statements to conform with the current period
presentation.
Net Loss Per Common Share - Basic and diluted net loss per common share are
calculated by dividing net loss attributable to common stockholders by the
weighted average number of shares of common stock outstanding during the period.
At September 30, 1999 and 1998, there were outstanding common stock equivalents
to purchase 90,535,319 and 38,413,473 shares of common stock, respectively, that
were not included in the computation of diluted net loss per common share as
their effect would have been anti-dilutive, thereby decreasing the net loss per
common share. Net loss per common share amounts have been restated for all
periods presented to reflect basic and diluted per share presentations.
The following table is a reconciliation of the net loss numerator of basic and
diluted net loss per common share for the three and nine months ended September
30, 1999 and 1998:
7
<PAGE>
Fonix Corporation and Subsidiaries
(A Development Stage Company)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
<TABLE>
<CAPTION>
Three months ended September 30,
-------------------------------------------------------------------------
1999 1998
-------------------------------- ------------------------------------
Per share Per share
Loss Amount Loss Amount
-------------------------------- ------------------------------------
<S> <C> <C> <C> <C>
Loss from continuing operations $ (7,050,344) $ (17,388,076)
Preferred stock dividends (1,031,288) (2,626,890)
--------------- ---------------
Net loss from continuing operations
attributable to common stockholders (8,081,632) $ (0.11) (20,014,966) $ (0.37)
Discontinued operations 3,654,499 0.05 (1,205,049) (0.02)
Extraordinary items 372,061 0.01 - -
---------------- ------------ --------------- --------------------
Loss attributable to common stockholders $ (4,055,072) $ (0.05) $ (21,220,015) $ (0.39)
================ ============ ================ =====================
Weighted average common shares
outstanding 76,479,555 54,020,736
================ ================
</TABLE>
<TABLE>
<CAPTION>
Nine months ended September 30,
-------------------------------------------------------------------------------
1999 1998
------------------------------------- -------------------------------------
Per share Per share
Loss Amount Loss Amount
------------------------------------- -------------------------------------
<S> <C> <C> <C> <C>
Loss from continuing operations $ (19,871,411) $ (33,987,567)
Preferred stock dividends (2,460,518) (2,626,890)
----------------- -----------------
Net loss from continuing operations
attributable to common stockholders (22,331,929) $ (0.33) (36,614,457) $ (0.73)
Discontinued operations 662,920 0.01 (1,205,049) (0.02)
Extraordinary items 372,061 0.01 - -
----------------- ------------- ---------------- -----------------
Loss attributable to common stockholders $ (21,296,948) $ (0.32) $ (37,819,506) $ (0.75)
================= ============= ================ =================
Weighted average common shares
outstanding 68,678,645 50,385,468
================ ================
</TABLE>
2. SALE OF THE HEALTHCARE SOLUTIONS GROUP
In September 1999, the Company completed the sale of the operations and a
significant portion of the assets of its HealthCare Solutions Group (the "HSG")
to Lernout & Hauspie Speech Products N.V. ("L&H"), an unrelated third party, for
up to $28,000,000. At the closing of this transaction, $21,500,000, less certain
credits of $194,018 was paid and $2,500,000 was deposited into an 18-month
escrow account in connection with the representations and warranties made by
Fonix in the sales transaction. Any remaining amount up to $4,000,000 is an
earnout contingent on the
8
<PAGE>
Fonix Corporation and Subsidiaries
(A Development Stage Company)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
performance of the HSG over the next two years. The Company will not record the
contingent earnout, if any, until successful completion of the earnout period.
The sale was approved by a majority of Fonix's stockholders. The proceeds from
the sale were used to reduce certain of the Company's liabilities and to provide
working capital to allow Fonix to focus on marketing and development
opportunities for its Interactive Technology Solutions Group. The assets sold
include inventory, property and equipment, certain prepaid expenses, purchased
core technology and other assets of the HSG. Additionally, L&H assumed the
capital lease obligations related to the HSG and the obligations related to
certain of the Company's deferred revenues.
On September 1, 1999, upon the closing of the Sale, the Company discontinued the
operations of the HSG. The results of operations of the HSG have been reported
separately as discontinued operations in the accompanying condensed consolidated
statements of operations. Prior year results have been restated to provide
comparability. The net assets (liabilities) of the HSG in the December 31, 1998
condensed consolidated balance sheet consist of the following:
<TABLE>
<CAPTION>
<S> <C>
Inventory $ 72,582
Other receivables 4,554
Deferred revenues (675,997)
--------------
Net current assets (liabilities) $ (598,861)
=============
Property and equipment, net of
accumulated depreciation of $27,367 $ 182,981
Intangible assets, net of accumulated
amortization of $828,886 19,379,131
Other assets 22,343
--------------
Net long-term assets $ 19,584,455
==============
</TABLE>
Revenues from HSG's operations were $1,726,262 for the period from January 1,
1999 to September 1, 1999 and $103,517 for the nine months ended September 30,
1998. These amounts have not been included in revenues reported in the
accompanying condensed consolidated statements of operations.
3. FORGIVENESS OF TRADE PAYABLES AND ACCRUED INTEREST
In September 1999, the Company negotiated reductions of $221,376 in amounts due
various trade vendors. Additionally, the Company negotiated reductions of
$150,685 in accrued interest owed to certain note holders. These amounts have
been accounted for as extraordinary items in the accompanying condensed
consolidated statements of operations.
4. ACQUISITIONS
The Company acquired AcuVoice, Inc. ("AcuVoice") in March 1998. AcuVoice
developed and marketed text-to-speech ("TTS") technologies and products directly
to end-users, systems integrators and original equipment manufacturers for use
in the telecommunications, multi-media, education and assistive technology
markets. In addition, the Company acquired PAI and Papyrus Development
Corporation ("PDC") (together with PAI, "Papyrus") in October 1998. PAI
developed, marketed and supported printing and cursive handwriting recognition
software for "personal digital assistants", pen tablets and mobile phones under
the trademark, Allegro(TM). PDC was a systems integration provider with
expertise and intellectual property in embedded systems and enhanced Internet
applications. The products and services formerly provided by AcuVoice and
Papyrus are now provided by the Company's Interactive Technologies Solutions
Group ("ITSG").
The Company also acquired Articulate Systems, Inc. ("Articulate") in September
1998. Articulate was a provider of voice recognition products to specialized
segments of the healthcare industry under the PowerScribe(R) trade name. The
9
<PAGE>
Fonix Corporation and Subsidiaries
(A Development Stage Company)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Company operated the Articulate business through the HSG. The operations and
substantially all the assets of the HSG were sold on September 2, 1999 (see Note
2). All of the acquisitions discussed above were accounted for as purchases.
The following unaudited pro forma financial statement data for the three and
nine months ended September 30, 1998 present the results of operations of the
Company as if the acquisitions of AcuVoice and Papyrus had occurred at January
1, 1998. The pro forma results have been prepared for comparative purposes only
and do not purport to be indicative of what would have occurred had the
acquisitions been made at January 1, 1998, or of future results. Purchased in-
process research and development related to the acquisition of AcuVoice of
$9,315,000 was expensed at the date of the AcuVoice acquisition and is not
presented in the following pro forma financial statement data since it is a
non-recurring charge directly attributable to the acquisition. Pro forma
financial information for the acquisition of Articulate has not been included in
the following pro forma financial statement as the operations and substantially
all the assets of the HSG were sold September 2, 1999 (see Note 2).
Additionally, the historical operating results of Articulate from the date of
acquisition through September 30, 1998 have been excluded from the pro forma
information.
<TABLE>
<CAPTION>
Three Months Ended Nine Months Ended
September 30,1998 September 30, 1998
------------------- -------------------
<S> <C> <C>
Revenues $ 145,185 $ 2,804,667
Net loss from continuing operations (13,932,394) (22,211,826)
Net loss from continuing operations
attributable to common stockholders (16,559,284) (24,970,376)
Basic and diluted net loss
per common share (0.31) (0.49)
</TABLE>
5. PAPYRUS SETTLEMENT
After the Papyrus acquisition closed in October 1998, the Company investigated
some of the representations and warranties made by Papyrus to induce the Company
to acquire the Papyrus companies. The Company determined that certain of the
representations made by Papyrus and its executive officers appeared to be
inaccurate. On February 26, 1999, the Company filed an action against the former
shareholders of Papyrus alleging misrepresentation and breach of contract. In
March and April 1999, five of the former shareholders of Papyrus filed actions
against the Company alleging default under the terms of the promissory notes
issued to them in connection with the Papyrus acquisition and certain other
claims. Subsequently, the Company entered into agreements with the five former
Papyrus shareholders for dismissal of the actions and cancellation of the
promissory notes upon payment to the former shareholders of $1,217,384 (the
"Settlement Payment") and return of 970,586 shares of restricted common stock
previously issued to the five former shareholders in connection with the
acquisition of Papyrus. The Company paid the Settlement Payment in September
1999 and the lawsuits described above have been dismissed.
6. INTANGIBLE ASSETS
Intangible assets consist of purchased core technology and goodwill arising from
the acquisitions of AcuVoice and Papyrus and direct costs incurred by the
Company in applying for patents covering its technologies. Amortization is
computed on a straight-line basis over the estimated useful lives ranging from
five to eight years. Total accumulated amortization was $3,757,780 and
$1,770,668 at September 30, 1999 and December 31, 1998, respectively, excluding
amortization of $828,886 related to HSG at December 31, 1998. The unamortized
portion of the purchased core
10
<PAGE>
Fonix Corporation and Subsidiaries
(A Development Stage Company)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
technology and goodwill related to the purchase of Articulate have been as a
result of the Sale. Additionally, the amount of goodwill associated with the
purchase of PAI was reduced by $1,415,908 in connection with the settlement
payment in September 1999 (see Note 5).
7. RELATED-PARTY AND OTHER NOTES PAYABLE
As of September 30, 1999, the Company had unsecured notes payable to former
Papyrus stockholders in the aggregate amount of $77,625, which notes were issued
in connection with the acquisition of Papyrus. The holders of these notes have
not made demand for payment.
During the nine months ended September 30, 1999, the Company paid, or otherwise
reduced through agreement (see Note 5), notes payable to various related parties
totaling $8,414,255, plus accrued interest.
In September 1999, the Company paid other notes payable to unrelated parties
aggregating $588,000 plus accrued interest. Additionally, a revolving note
payable in the amount of $50,000 was paid by a former employee and is included
as an account payable.
A revolving note payable in the amount of $19,988,193 at December 31, 1998, plus
accrued interest, was paid in full in January 1999.
8. SERIES C 5% CONVERTIBLE DEBENTURES
On January 29, 1999, the Company entered into a Securities Purchase Agreement
with four investors pursuant to which the Company sold its Series C 5%,
Convertible Debentures (the "Debentures") in the aggregate principal amount of
$4,000,000. The outstanding principal amount of the Debentures is convertible at
any time at the option of the holders into shares of the Company's common stock
at a conversion price, subject to adjustment, equal to the lesser of $1.25 or 80
percent of the average of the closing bid price of the Company's common stock
for the five trading days immediately preceding the conversion date. The Company
recorded $687,500 as interest expense upon the issuance of the Debentures in
connection with this beneficial conversion feature. The Company also issued
400,000 warrants to purchase an equal number of the Company's common shares at a
strike price of $1.25 per share in connection with this financing. The warrants
are exercisable for a period of three years from the date of grant. The
estimated fair value of the warrants of $192,000, as computed under the
Black-Scholes pricing model, was recorded as interest expense upon the issuance
of the Debentures. On March 3, 1999, the Company executed a supplemental
agreement pursuant to which the Company agreed to sell another $2,500,000
principal amount of Debentures on the same terms and conditions as the January
29, 1999 agreement, except no additional warrants were issued. The Company
recorded $1,062,500 as interest expense upon the issuance of the additional
Debentures in connection with the beneficial conversion feature. The obligations
of the Company for repayment of the Debentures, as well as its obligation to
register the common stock underlying the potential conversion of the Debentures
and the exercise of the warrants issued in these transactions, are personally
guaranteed by the Guarantors (see Note 10). In connection with the March 3, 1999
funding, the Company agreed to grant a lien on the patent covering the Company's
Automated Speech Recognition ("ASR") technologies as collateral for repayment of
the debentures. However, to date no lien on the patent has been granted. The
Guarantors guaranteed the obligations of the Company under the Debentures and
pledged 6,000,000 shares of common stock of the Company beneficially owned by
them as collateral security for their obligations under their guarantee.
The outstanding principal amount of the Debentures bears interest at a rate of
5%, payable on March 31, June 30, September 30, and December 31, and on each
conversion date, of each year during the term of the Debentures. In addition,
the interest on the outstanding principal amount of the Debentures may, at the
Company's option, be paid in shares of the Company's Class A common stock
calculated based upon the Debenture Conversion Price on the date such
11
<PAGE>
Fonix Corporation and Subsidiaries
(A Development Stage Company)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
interest becomes due. The Company has not paid interest on the Debentures at any
time since they were issued. Under the terms of the Debentures, the investors
could charge penalties for such failure. However, the investors have waived all
such penalties accruing prior to October 1, 1999.
Under the terms of the Debentures, in the event that the Company fails to file
and have declared effective the registration statement registering the shares
underlying the Debentures, the holders of the Debentures may elect penalty
provisions to (a) reduce the conversion price by 2.5% per month until the
registration statement is declared effective, or (b) receive 2.5% of the
outstanding principal amount of Debentures per month, in cash. To date, the
Company has not filed the registration statement or had it declared effective as
required. However, all holders waived the penalty provisions through June 30,
1999. Additionally, some holders of the Debentures agreed to a partial waiver of
their penalty provisions through September 30, 1999. The holders of the
Debentures have agreed to waive the penalty provisions, contingent on the
registration statement being declared effective by February 29, 2000. In the
event that the registration statement is not declared effective by that date,
the penalty provisions automatically apply, retroactive to October 1, 1999.
Subsequent to the March 3, 1999, funding, the holders of the Debentures notified
the Company and the Guarantors that the Guarantors were in default of certain
terms of the stock pledge agreement executed by the Guarantors in favor of the
holders as a result of the Company's failure to register the resale of the
shares underlying the Debentures, and that the holders may therefore exercise
their right to sell the shares pledged by the Guarantors. The holders of the
Debentures have subsequently informed the Company that they have sold the
6,000,000 shares pledged by the Guarantors and that proceeds from the sale of
the pledged shares has aggregated $3,278,893. Of this total, $406,250 related to
penalties attributable to default provisions of the stock pledge agreement and
recorded was as interest expense and $343,750 related to provisions of the
Series D Preferred Stock and has been recorded as preferred stock dividends.
Both of these amounts were recorded during the three months ended September 30,
1999. The remaining $2,528,893 of the proceeds was applied as a reduction of the
principal balance of the Debentures as of September 30, 1999. Additional
interest payable under the provisions of the stock pledge and related
indemnification agreements has been recorded by the Company as an accrued
liability in the amount of $731,250. Under its indemnity agreement in favor of
the Guarantors, the Company will issue 6,000,000 replacement shares to the
Guarantors for the shares sold by the holders and reimburse the Guarantors for
any costs incurred as a result of the holders' sales of the Guarantors' shares
(see Note 10).
On December 3, 1999, the Company received notice that its Class A common stock
had been delisted from the Nasdaq SmallCap Market. The delisting was an event of
default under the terms of the Debentures. Upon the occurrence of this event of
default, the outstanding principal amount of the Debentures, together with
accrued interest, became immediately due and payable in cash. However, the
holders of the Debentures waived this event of default.
9. STOCKHOLDERS' EQUITY
Common Stock Subject to Redemption - On December 21, 1998, the Company entered
into a private placement securities agreement. Pursuant to the agreement, the
Company received $1,980,000 in net proceeds in exchange for 1,801,802 shares of
redeemable common stock, an equal number of "Repricing Rights," Repurchase
Rights, and warrants to purchase 200,000 shares of common stock. Each Repricing
Right entitles the holder to receive a number of additional shares of common
stock for no additional consideration according to a formula ("Repricing
Rights") based on the lowest closing bid price of the Company's common stock
during the 15 consecutive trading days immediately preceding the exercise date
and a repricing price, as defined, ranging from $1.3875 to $1.4319 depending
upon the date of the exercise. The repricing rights became exercisable on March
21, 1999.
Each holder of the Repurchase Rights has the right, based on certain conditions,
to require the Company to repurchase all or a portion of the holder's common
shares or Repricing Rights. The Repurchase Rights may only be exercised
simultaneously with or after the occurrence of a major transaction or triggering
event. Major transactions and triggering
12
<PAGE>
Fonix Corporation and Subsidiaries
(A Development Stage Company)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
events consist of, among others, certain consolidations, mergers or other
business combinations, the sale or transfer of all or substantially all the
Company's assets, a purchase, tender or exchange offering of more than 40
percent of the Company's outstanding common stock made and accepted, the failure
to have a related registration statement declared effective prior to June 19,
1999 or a suspension from listing or delisting of the Company's common stock for
a period of more than three days. As a registration statement registering the
shares and the shares underlying the Repricing Rights was no declared effective
by June 19, 1999, and the Company's Class A common stock has been delisted from
the Nasdaq SmallCap Market, the holders had the right to exercise the Repurchase
Right. However, the holder has waived its right to exercise the repurchase
option as a result of the delisting of the Class A common stock from the Nasdaq
SmallCap Market and deferred until March 1, 2000, its right to require
repurchase as a result of the Company's failure to register the shares
underlying the Repurchase Rights and the Class A common stock. If such shares
are not registered before March 1, 2000, the holder may exercise the Repurchase
Rights.
The repurchase price for the common stock is $1.3875 per share. The repurchase
price for the Repricing Rights is based on a formula using the Repricing Rate
and the last reported sale price of the Company's common stock on the date of
the exercise of the repurchase right.
Series D and E Preferred Stock - During the nine months ended September 30,
1999, 131,667 shares of Series D preferred stock and 135,072 shares of Series E
preferred stock, together with related dividends on each, were converted into
8,467,129 shares and 5,729,156 shares, respectively, of the Company's common
stock. After the above conversions 876,667 shares of Series D preferred stock
remain outstanding.
On December 3, 1999, the Company received notice that its Class A common stock
had been delisted from the Nasdaq SmallCap Market, in part because the stock
price had been below $1.00 per share since approximately March 1999 (see Note
15). However, the Company's Class A common stock is currently trading on the OTC
Bulletin Board.
The delisting of the Company's Class A common stock from the Nasdaq SmallCap
Market was an event of default under the terms of the Series D preferred stock.
Upon the occurrence of an event of default, the Company was required to pay to
each holder of Series D preferred stock a fee of two percent of the purchase
price of the Series D preferred stock in cash for each month during which the
stock is delisted. However, the holders of the Series D preferred stock have
waived this event of default.
Common Stock - The Company incurred an obligation to issue 6,000,000 shares of
common stock to two individuals who are executive officers and directors and one
individual who is a former officer and director of the Company in satisfaction
of an indemnification agreement wherein the Company was required to pay any sums
the three individuals paid for the benefit of the Company. The shares are to be
issued to replace shares beneficially owned by the three individuals and sold by
the holders of the Debentures and Series D preferred stock (see Note 10).
On June 2, 1999, the Company issued 200,000 shares of common stock (having a
market value of $100,000 on that date) to an unrelated individual in payment for
consulting services rendered.
In April 1999, five former PAI shareholders agreed to cancel 970,586 shares of
common stock to the Company reducing the total shares they had received from the
Company in the 1998 acquisition of PAI from 3,111,114 shares to 2,140,528
shares. The shares were effectively canceled in September 1999 in connection
with the Settlement Payment (see Note 5). The original fair market value of
$1,000,917 associated with the canceled shares is reflected as a reduction to
goodwill associated with the purchase of PAI.
13
<PAGE>
Fonix Corporation and Subsidiaries
(A Development Stage Company)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
As of September 30, 1999
Common Stock Options - During the nine months ended September 30, 1999, the
Company granted 754,500 stock options to employees at exercise prices ranging
from $0.59 to $1.78 per share. Additionally, 9,500 stock options were granted to
two consultants for services provided to the Company. The fair market value of
the consultant options was $1.32 per share, or $12,540 in total, using the
Black-Scholes pricing model and was charged to product development and research
expense. The term of all options granted during this nine month period is ten
years from the date of grant. Of the stock options issued, 726,334 vested
immediately, 18,834 vest six months after issuance and 18,832 vest one year
after issuance. The weighted average fair value of the options granted to
employees during the nine months ended September 30, 1999 was $1.31 per share
using the Black-Scholes pricing model. Had compensation expense for the issuance
of these options been recorded in accordance with the method prescribed by SFAS
No. 123, "Accounting for Stock-Based Compensation", the Company's net loss from
continuing operations attributable to common stockholders would have been
$22,281,723 or $0.32 per share for the nine months ended September 30, 1999. As
of September 30, 1999, the Company had a total of 15,536,582 options
outstanding.
Effective May 7, 1998, the Company entered into a one-year professional services
agreement with a public relations firm. The minimum monthly retainer was $15,000
per month. In connection with this agreement, the firm was granted options to
purchase 100,000 shares of the Company's common stock at $3.75 per share. In May
1999, the Company negotiated a termination of this agreement for a cash payment
of approximately $33,000 and the grant of options was rescinded.
Common Stock Warrants - During the nine months ended September 30, 1999, the
Company granted warrants to L&H in connection with loans made to the Company in
April and May 1999 totaling $6,000,000. These warrants allow L&H to purchase
850,000 shares of common stock of the Company at exercise prices ranging from
$0.60 to $0.70 per share. Of these warrants, 250,000 expired October 18, 1999
without being exercised. The remaining 600,000 warrants expire May 17, 2001. The
fair value of the warrants was $0.14 and $0.35 per share for the 250,000 and
600,000 warrants, respectively, using the Black-Scholes pricing model. The value
of the warrants totaled $246,240 and was amortized as a financing expense over
the term of the loans.
On February 11, 1998, the Company entered into a First Statement of Work and
License Agreement with Siemens Semiconductor Group of Siemens Aktiengesellschaft
("Siemens") under which the Company and Siemens are jointly pursuing the
development of Siemens' integrated circuits incorporating ASR and other related
technologies for use in certain telecommunications applications. In connection
with the license agreement Siemens purchased warrants to acquire 1,000,000
shares of restricted common stock at an average exercise price of $20 per share
with expiration dates ranging from December 31, 1998 to December 31, 1999. As of
September 30, 1999, 800,000 of the warrants originally issued had expired and
200,000 of the warrants remain outstanding at an average exercise price of
$30.00 per share.
As of September 30, 1999, the Company had a total of 2,475,000 warrants
outstanding.
10. RELATED-PARTY TRANSACTIONS
Related-party transactions with entities owned by two individuals who are
executive officers and directors and one individual who is a former officer and
director of the Company for the nine months ended September 30, 1999 and 1998
were as follows:
<TABLE>
<CAPTION>
1999 1998
------------- ---------------
<S> <C> <C>
Expenses:
Base rent $ 93,312 $ 83,788
Leasehold improvements $ - $ 35,247
</TABLE>
14
<PAGE>
Fonix Corporation and Subsidiaries
(A Development Stage Company)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
The Company rents office space under a month-to-month lease from Studdert
Companies Corporation ("SCC"). SCC is owned by the three individuals described
above. The lease from SCC is guaranteed by the three individuals. The lease
requires monthly payments of $10,368. The Company believes the terms of the
related-party lease are at least as favorable to the Company as the terms that
could have been obtained from an unaffiliated third party in a similar
transaction.
Guaranty of Company Obligations and Related Indemnity Agreement - The Guarantors
have guaranteed certain obligations of the Company (see Note 8), including the
Company's obligations under the Debentures. As security for some of the
guarantees, the Guarantors pledged shares of Fonix common stock beneficially
owned by them. In September 1999, the Company paid in full a note payable to an
unrelated third party that had previously been guaranteed by the Guarantors. The
Guarantors pledged 6,000,000 shares of the Company's common stock beneficially
owned by them as collateral security for the Company's obligations regarding the
Debentures.
The Company agreed to indemnify the Guarantors if they were required to pay any
sums for the benefit of the Company under their guaranty of provisions of the
Debentures. The indemnity agreement provides that the Company will issue shares
of the Company's common stock of sufficient value to reimburse the Guarantors in
full, plus interest at 10 percent per annum, for all costs associated with
meeting the guarantee commitment, including any income taxes resulting
therefrom. Additionally, in consideration for the pledge of the Company's common
shares as collateral for the Debentures, the Board of Directors authorized the
issuance to the Guarantors of one common stock purchase warrant for every three
shares pledged. However, subsequent to the Board of Directors' authorization,
the Guarantors declined to accept the warrants and they were not issued.
Subsequent to the March 3, 1999, funding, the holders of the Debentures notified
the Company and the Guarantors that the Guarantors were in default of certain
terms of the stock pledge agreement as a result of the Company's failure to
register in a timely manner the resale of the shares underlying the Debentures,
and that the holders may exercise their right to sell the shares pledged by the
Guarantors. The holders of the Debentures have subsequently informed the Company
that proceeds from the sale of the 6,000,000 pledged shares has aggregated
$3,278,893. Under its indemnity agreement in favor of the Guarantors, the
Company is obligated to issue 6,000,000 replacement shares to the Guarantors for
the shares sold by the holders of the Debentures. Additionally, the Company has
recorded a related party liability of $1,296,600 as a reimbursement to the
Guarantors for the income taxes incurred by the Guarantors as a result of the
holders' sales of the Guarantors' shares.
In December 1998, the Guarantors guaranteed certain additional obligations of
the Company. As security for some of the guarantees, the Guarantors also pledged
shares of the Company's common stock beneficially owned by them. In March 1999,
143,230 of the shares previously pledged by the Guarantors to a bank were sold
by the bank and the proceeds were used to pay Company credit card balances and
the related accrued interest in full totaling $244,824. In May 1999, 100,000 of
the shares previously pledged by the Guarantors to another creditor of the
Company were sold by the creditor and the proceeds, totaling $72,335, were used
to pay amounts owed by the Company.
As of September 30, 1999, no guarantees remain outstanding. However, the Company
anticipates that in the future the Guarantors may request that the Company
provide indemnity and/or compensation for the guarantees, advances and/or
pledges by the Guarantors for the benefit of the Company. To the extent such
requests, if any, are reasonable and of a nature similar to what the Company
would grant to unrelated parties in similar transactions, the Company presently
anticipates that it will submit any such requests to the Board of Directors for
consideration.
15
<PAGE>
Fonix Corporation and Subsidiaries
(A Development Stage Company)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
11. PRODUCT DEVELOPMENT AND RESEARCH
Synergetics - In October 1993, the Company entered into an agreement with
Synergetics, a research and development entity, to develop certain technologies
related to the Company's ASR technologies. Under the terms of the Synergetics
agreement, the Company expended $186,455 during the nine months ended September
30, 1999 for product development and research efforts. No amounts were expended
during the three months ended September 30, 1999.
IMC2 - In March 1998, the Company entered into a professional services agreement
with IMC2, a research and development entity, to provide assistance to the
Company in the development of specific ASR technologies. The President of IMC2
is also the President of Synergetics. The professional services agreement is for
a term of 36 months and requires the Company to make monthly payments of
$22,000. Under the terms of the agreement, the Company expended $66,000 and
$198,000 during the three and nine months ended September 30, 1999,
respectively.
Adiva- Beginning in 1998, the Company utilized the research and development
services of Adiva. The president of Adiva is also the president of Synergetics
and IMC2. The Company expended $63,395 during the nine months ended September
30, 1999 for research and development efforts. No amounts were expended during
the three months ended September 30, 1999.
12. COMMITMENTS AND CONTINGENCIES
Employment Agreements - In January 1998, the Company entered into employment
contracts with two employees which expire in January 2001. The minimum annual
salary payments required by these contracts total $405,000. In January 1999, the
Company announced a cost reduction program for the Company's 1999 operating year
wherein the two employees referred to above agreed that their compensation would
be reduced 30 percent effective February 1999.
Executive Employment Agreements - On November 1, 1996, the Company entered into
employment contracts with three executive officers (one of whom is no longer an
executive officer) which expire on December 31, 2001. The annual base salary
pursuant to the contracts with each executive officer for the year ended
December 31, 1999 is $425,000. In January 1999, the Company announced a cost
reduction program for the Company's 1999 operating year wherein the two
remaining executive officers agreed that their annual compensation would be
reduced to $297,500 commencing February 1999. At the same time, Stephen M.
Studdert resigned as the Company's Chief Executive Officer. His employment
agreement was canceled and he entered into a separation agreement pursuant to
which he will be paid $250,000 per year through January 31, 2001 and $100,000
for the year ended January 31, 2002.
Sublease of Office Facilities - Effective May 14, 1999, the Company entered into
an agreement to sublease 10,224 square feet of its Draper, Utah facility to an
unrelated third party. The agreement requires the sublessee to pay $13,961 per
month, or approximately 40 percent of the Company's monthly obligation under the
primary lease agreement through December 31, 2000. The sublessee has the option
to extend the term by two additional three-month periods.
Effective May 25, 1999, the Company entered into an agreement to sublease 8,048
square feet of a total 10,048 square feet of its Cupertino, California facility
to an unrelated third party. The remaining 2,000 square feet occupied by the
Company may be turned over to the sublessee no sooner than six months nor later
than nine months from the commencement of the sublease. The agreement requires
the sublessee to pay $28,346 per month, or approximately 80 percent of the
Company's obligation under the primary lease agreement through the six to nine
month period of reduced occupancy by the Company and 100 percent thereafter
through May 31, 2003.
Operating Lease - In March 1999, the Company entered into an agreement to lease
office space in Cleveland, Ohio for sales and installation personnel of the HSG.
The lease is for three years at a monthly rate of $4,260 and became effective
May 1, 1999. Future aggregate minimum obligations under this operating lease are
$144,840. Under the terms of the sale of the HSG, L&H assumed this operating
lease obligation in September 1999.
16
<PAGE>
Fonix Corporation and Subsidiaries
(A Development Stage Company)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Capital Lease Obligations - In January 1999, the Company entered into a
noncancelable capital lease arrangement for telephone equipment at its HSG
facility in Woburn, Massachusetts. In May 1999, the Company entered into a
noncancelable capital lease arrangement for telephone equipment at its HSG
facility in Cleveland, Ohio. Future aggregate minimum obligations under these
capital leases, net of amounts representing interest, aggregate approximately
$51,000. Under the terms of the sale of the HSG, L&H assumed these capital lease
obligations in September 1999.
Royalty Agreements - The Company has entered into various technology license
agreements. Generally, the agreements require the Company to pay royalties at
specified dollar amounts in connection with each product sold that utilizes
technologies licensed by the Company under these agreements. Royalty expense is
accrued at the time product revenues incorporating the licensed technologies are
recognized. There were no sales of products incorporating these licensed
technologies during the nine months ended September 30, 1998. Royalty expenses
of $37,238 and $100,763, all related to the HSG, were incurred during the three
and nine months ended September 30, 1999, respectively, and have been included
in the loss from discontinued operations.
13. LITIGATION
Clarke - On August 28, 1998, John R. Clarke and Perpetual Growth Fund, a company
Clarke's spouse purportedly owns, commenced an action against the Company in
federal court for the Southern District of New York. Clarke and Perpetual Growth
asserted claims for breach of contract relating to certain financing the Company
received during 1998. Specifically, Clarke and Perpetual Growth alleged that
they entered into a contract with the Company under which the Company agreed to
pay them a commission of five percent of all financing provided to Fonix by
Southridge Capital Management or its affiliates. Clarke and Perpetual claim that
they are entitled to commissions with respect to approximately $3,000,000 of
equity financing to the Company in July and August 1998, and the Company's
offerings of Series D and Series E preferred stock, totaling together
$12,000,000, in August and September 1998.
The Company believes that the Clarke lawsuit is without merit and filed a motion
to dismiss based upon the court's lack of personal jurisdiction over the
Company. The court granted the Company's motion to dismiss. Clarke and Perpetual
Growth appealed the dismissal and their appeal has been denied. The Company has
filed a suit against Clarke and Perpetual Growth in federal court for the
Central District of Utah seeking a declaratory judgment that it does not owe any
money to Clarke and Perpetual Growth. Now that the action in New York has been
dismissed and the appeal denied, the Company intends to vigorously pursue the
Utah action. However, the lawsuit in New York could be reinstated on appeal and
Clarke and Perpetual Growth could prevail in that lawsuit, in which case the
Company may be required to pay significant amounts of money damages awarded by
the court.
OGI - On July 28, 1999, Oregon Graduate Institute ("OGI") filed a notice of
default, demand for mediation and demand for arbitration with the American
Arbitration Association. In its demand, OGI asserted that Fonix was in default
under three separate agreements between the Company and OGI in the total amount
of $175,000. On or about September 23, 1999, the Company responded to OGI's
demand and denied the existence of a default under the three agreements
identified by OGI. Moreover, the Company asserted a counterclaim against OGI in
an amount not less than $250,000. The arbitrator appointed by the American
Arbitration Association will conduct a scheduling conference in January 2000 to
set dates for the proceeding, including the date of the arbitration hearing.
In addition to the above, the Company is involved in various lawsuits, claims
and actions arising in the ordinary course of business. In the opinion of
management, after consultation with legal counsel, the ultimate disposition of
these matters will not materially affect the consolidated financial position or
results of operations of the Company.
17
<PAGE>
Fonix Corporation and Subsidiaries
(A Development Stage Company)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
14. REPORTABLE SEGMENTS
The Company has adopted SFAS No. 131, "Disclosures about Segments of an
Enterprise and Related Information". This statement requires disclosures related
to components of a company for which separate financial information is available
and evaluated regularly by the Company's chief operating decision makers in
deciding how to allocate resources and in assessing performance. As a result of
the sale of the HSG in September 1999 (see Note 2), management believes that the
Company has only one operating segment because the Company's remaining core
business consists only of operations derived from the Interactive Technologies
Solutions Group.
15. SUBSEQUENT EVENTS
Shareholders Meeting - At the Company's annual shareholder meeting held October
29, 1999, 59,497,418 shares were represented in person or by proxy. The
shareholders approved amendments to the Company's certificate of incorporation
that (A) created a new class of common stock designated as Class B Non-Voting
Common Stock with 1,985,000 Class B shares authorized; and (B) redesignated the
Company's current common stock as Class A Common Stock and changed each share of
existing common stock into a share of Class A Common Stock. Additionally, the
shareholders approved an amendment to the Company's certificate of incorporation
that increased the number of common shares authorized to be issued from
100,000,000 to 300,000,000 and increased the number of authorized preferred
shares from 20,000,000 to 50,000,000. The Class B shares were authorized to
provide for the conversion of 1,935,000 common shares issued in the acquisition
of Articulate Systems, Inc., to a non-voting class of stock as provided in the
acquisition agreement. The Company does not intend to register its Class B
Non-Voting Common Stock. The shareholders also approved a series of transactions
pursuant to which the Company issued its Series D 4% preferred stock and Series
E 4% preferred stock.
Appointment of Director - Effective October 29, 1999, Mark S. Tanner was
appointed as a member of the Company's Board of Directors. Mr. Tanner becomes
the second independent member appointed to the Board of Directors during 1999.
Previously, on September 2, 1999, William A. Maasberg, Jr. was appointed as an
independent member of the Company's Board of Directors.
Conversion of Series D Preferred Stock - Subsequent to September 30, 1999, a
total of 494,944 shares of Series D preferred stock, together with related
dividends, were converted into 38,785,1425 shares of the Company's common stock.
After the above conversions 381,723 shares of Series D preferred stock remain
outstanding.
Delisting from the Nasdaq SmallCap Market - Until recently, the Company's Class
A common stock traded on the Nasdaq SmallCap market which requires, for
continued listing, a minimum bid price of at least $1.00 per share. At June 29,
1999, the Company's Class A common stock had traded below $1.00 for more than
thirty consecutive trading days. On June 29, 1999, the Company received a letter
from Nasdaq indicating that unless the minimum bid price for the Company's Class
A common stock returned to at least $1.00 per share for at least ten consecutive
trading days prior to September 29, 1999, the Company's shares would be delisted
from the Nasdaq SmallCap Market on October 1, 1999. The Company appealed
Nasdaq's notice and listing determination in September 1999. Nasdaq held a
hearing on the matter on October 28, 1999.
On December 3, 1999, the Company received notice that its Class A common stock
had been delisted from the Nasdaq SmallCap Market, in part because the stock
price had been below $1.00 per share since approximately March 1999. The Company
is currently evaluating its options, including the possibility of appealing the
delisting decision. However, the Company's Class A common stock is currently
trading on the OTC Bulletin Board.
Additionally, the delisting of the Company's Class A common stock from the
Nasdaq SmallCap Market was an event of default under the terms of the
Debentures. Upon the occurrence of an event of default, the outstanding
principal amount of all of the Debentures, together with accrued interest and
all other amounts owing in respect thereof, became immediately due and payable
in cash. However, the holders of the Debentures have waived this event of
default.
18
<PAGE>
Fonix Corporation and Subsidiaries
(A Development Stage Company)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Finally, the delisting of the Company's Class A common stock from the Nasdaq
SmallCap Market was a triggering event giving rise to certain repurchase rights
in connection with the Company's Series D and Series E preferred stock. The
holders of the Repurchase Rights had the right to require Fonix to repurchase
some or all of the investor's Class A common shares and Repricing Rights.
However, the holders have waived this event of default.
Recent Financing Activities -Fonix has recently entered into an agreement with
four investors whereby Fonix intends to sell to the investors a total of 250,000
shares of its Series F 6% Convertible Preferred Stock (the "Series F Preferred
Stock"), in return for payment of $5,000,000. It is anticipated that the Series
F Preferred Stock will be convertible into shares of Fonix's Class A common
stock during the first six months following the closing of the transaction at a
price of $0.75 per share, and thereafter at a price equal to 90% of the average
of the three lowest closing bid prices in the twenty-day trading period prior to
the conversion of the Series F Preferred Stock. Fonix anticipates that the
investors will receive registration rights which will require Fonix to file a
registration statement covering the shares underlying the Series F Preferred
Stock, and that Fonix will have the option of redeeming any outstanding Series F
Preferred Stock. Although Fonix has received approximately $1,000,000 as an
advance in connection with this financing, the securities purchase agreement has
not been signed. Accordingly, the terms may differ from those set forth in this
paragraph.
19
<PAGE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
THIS QUARTERLY REPORT ON FORM 10-Q CONTAINS, IN ADDITION TO HISTORICAL
INFORMATION, FORWARD-LOOKING STATEMENTS THAT INVOLVE SUBSTANTIAL RISKS AND
UNCERTAINTIES. THE COMPANY'S ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THE
RESULTS ANTICIPATED BY THE COMPANY AND DISCUSSED IN THE FORWARD-LOOKING
STATEMENTS. FACTORS THAT COULD CAUSE OR CONTRIBUTE TO SUCH DIFFERENCES ARE
DISCUSSED IN THE COMPANY'S ANNUAL REPORT ON FORM 10-K, AS AMENDED, FOR THE YEAR
ENDED DECEMBER 31, 1998.
Overview
Corporate Summary
Fonix is a development stage company engaged in marketing and developing of
proprietary human/computer interaction technologies. Specifically, the Company
has developed neural network-based automated speech recognition ("ASR"), as well
as text-to-speech ("TTS"), handwriting recognition ("HWR") and speech
compression technologies packaged in products salable to a wide range of
customers. (ASR, TTS, HWR and speech compression technologies are sometimes
collectively referred to as "core technologies".) The Company expects to
continue to make commercially available products utilizing its core technologies
which enable computers and electronic devices to interact with people on human
terms rather than humans conforming to the process of a machine. The Company
believes this new efficient, intuitive and natural method of human/computer
interaction will eventually replace traditional interaction tools such as the
keyboard and mouse in a broad range of mass market, industrial, embedded and
server-based applications.
Fonix is pursuing revenue opportunities through generation of
non-recurring engineering fees, product and technology license royalties,
product sales and product support maintenance contracts. The Company markets its
products and core technologies to software developers, consumer electronic
manufacturers (including producers of computer processors or chips), third party
product developers, operating system developers, network and share-ware
developers and Internet and web related companies. The Company focuses marketing
toward both embedded systems applications and server-based solutions for
Internet and telephony voice activated applications.
Manufacturers of consumer electronic products, software development and
Internet content use Fonix core technologies to simplify the use of their
products and increase product functionality resulting in broader market
opportunities and significant competitive advantage. Unlike traditional
stand-alone consumer speech and language technologies, Fonix solutions support
multiple platforms, are environment and speaker independent, while providing
easy integration within a relatively small memory requirement.
Competitive Advantages of Core Technologies
Fonix core technologies have key competitive advantages that
differentiate them from other speech and handwriting technology companies.
ASR. Fonix researchers have developed and patented what the Company
believes to be a fundamentally new and unique approach to the analysis of human
speech sounds and the contextual recognition of speech. The core ASR
technologies attempt to approximate the techniques employed by the human
auditory system and language understanding centers in the human brain. The ASR
technologies use information in speech sounds perceptible to humans but not
discernible by current ASR systems. The ASR technologies also employ neural
network technologies (artificial intelligence techniques) for identifying speech
components and word sequences contextually, similar to the way in which
scientists believe information is processed by the human brain. As presently
developed, the phonetic sound recognition engine is comprised of several
components including audio signal processing, a feature extraction process, a
phoneme estimation process, and a linguistic process based on proprietary neural
net technologies that are designed to interpret human speech contextually. This
development has yielded a proprietary ASR system utilizing a unique front-end
analysis of the acoustic speech signal, a neural net-based phoneme identifier,
and a neural-net
20
<PAGE>
architecture for back-end language modeling. The latter component is known as
MULTCONS or multi-level temporal constraint satisfaction network. These
developments have been the subject of two issued patents and several pending
patents. In addition, the Company has acquired a related patent covering the
front-end recognition process.
The Company believes the reliable recognition of natural, spontaneous
speech spoken by one or more individuals in a variety of common environments by
means of a conveniently placed microphone will significantly improve the
performance, utility and convenience of applications such as computer command
and control, voice activated navigation of the Internet, data input, text
generation, telephony transactions, continuous dictation, and other applications
in both embedded and server based applications.
Fonix has pursued the development of these ASR technologies to produce
salable products and gain market share by overcoming the limitations of
currently available commercial ASR systems and broadening the market acceptance
and use of human/computer interaction technologies. Key benefits resulting from
Fonix proprietary ASR technologies which differentiate Fonix ASR products and
technologies from other currently available competitive products include:
1. Significantly reduced computer memory requirements allowing speech
recognition to operate in embedded system environments, or enabling
server-based systems to operate with significantly more simultaneous
users because memory requirements do not encumber as much operating
system resources as competitive traditional systems.
2. Significantly reduced power requirements making Fonix technologies
available for use in a host of smaller computing solutions with limited
battery/power capacity and enabling more simultaneous users on
server-based systems.
3. Speaker independence allowing various speakers to use the same system
without the system being trained to a particular user's voice and
dialect.
4. Excellent noise cancellation qualities allowing the ASR system to
extract ambient background noise, thus allowing higher recognition
rates in noisy environments.
5. Highly reduced need for headsets or tethered microphones.
6. Rapid porting to multiple computer chip platforms and operating
systems to create broad product demand. 7. The Fonix Accelerated
Applications Speech Technology (FAAST) product is a leading edge,
visual, integrated development environment which allows customers to
build applications in a rapid time frame with a high rate of success
and little outside resources thereby accelerating product time to
market.
The Company believes that its ASR technologies offer unique speech
processing techniques that will improve a broad range of computing solutions and
accelerate and enhance integration of human/computer interaction technologies
into products, applications, solutions and devices.
Although these plans represent management's beliefs and expectations
based on its current understanding of the market and its experience in the
industry, there can be no assurance that actual results will meet these
expectations. See "Certain Significant Risk Factors." During 1998 and 1997, the
Company has expended $12,109,065, and $7,066,294, respectively, on ASR research
and development activities. Since its inception (October 1, 1993), the Company
has spent $35,365,904 on research and development ("R&D") of its ASR
technologies. The Company expects that a substantial part of its capital
resources will continue to be devoted to research and development of ASR
technologies and other proprietary technologies for the foreseeable future.
TTS. Fonix text-to-speech products include a small, proprietary
vocabulary-true human-quality synthetic voice with full prosody and an unlimited
vocabulary text-to-speech engine initially developed by AcuVoice and purchased
by Fonix in 1998. All TTS products are sold under the Fonix brand name.
The Company's TTS products began as a new approach to synthesized
speech, a system using actual recordings of "units" of human speech (i.e., the
sound pulsation). Since the unit of speech often consists of more than one
phoneme (sound), Fonix's approach has been called a "large segment concatenative
speech synthesis" approach. Other companies such as DEC and AT&T began in the
early 1960s and continue until the present to use a method called "parametric
speech synthesis." Parametric systems have problems of speech quality, because
their unit is not an actual recording,
21
<PAGE>
but a computer's version of what a human voice sounds like. Poor speech quality
also occurs because the parametric unit consists, for the most part, of a single
phoneme, such as the "t" in the word "time." Fonix synthetic speech products
have been recognized as high quality, human sounding engines which include full
voice inflection, intonation and clarity. Fonix' large vocabulary TTS ("LVTTS")
engine won awards as "best text-to-speech" product at the Computer Technology
Expo '97 and '98 and the best of show award at AVIOS '97. Presently LVTTS
products are sold to end-users, systems integrators and OEMs in
telecommunications, multi-media, educational and assistive technology markets.
The products include the Fonix AV 1700 TTS system for end-user desktop
and laptop system use. The Fonix AV 2001 SDK is a software development kit for
developers of telephony applications. Run-time software licenses for the AV 2001
are offered for applications developed with the SDK. The SDK supports major
computer telephony platforms.
During the nine months ended September 30, 1999, the Company received
in the aggregate, $348,726 in revenue from licensing or sale of the TTS
technologies and products compared to pro-forma revenue of $246,382 for the
comparable nine month period of 1998.
HWR. In October 1998, Fonix acquired Papyrus Associates, Inc.
("Papyrus"), including its Allegro handwriting recognition software. The Allegro
handwriting recognition software is a single letter recognition system like the
popular Graffiti handwriting recognition software for the PalmPilot PDA.
However, Allegro's alphabet is all natural in appearance involving lower case
letter making. The Allegro system is easy to use and requires practically no
learning. Allegro is sold by Purple Software in England for the Psion Series 5
hand-held PC. This software has also been licensed to Philips for use with its
line of smart cell phones. Allegro is also the subject of a sales agreement with
Lucent Technologies for use in its Inferno operating system. Papyrus has also
developed cursive handwriting recognition software which recognizes
naturally-written whole words. This cursive technology is only available as a
licensed product to OEM customers. Both the Allegro and the cursive handwriting
recognition software are user independent and require no training on the
software.
During the nine months ended September 30, 1999, the Company received
$2,357 in revenue from licensing or sale of the handwriting recognition
technologies compared to pro-forma revenue of $190,147 for the comparable nine
month period of 1998.
Market Strategy
The world-wide market for ASR, TTS and HWR technologies and products is
newly emerging. Currently, only a small portion of prospective applications for
these human/computer interaction technologies has reached the critical point of
commercial viability. Among the largest current markets developing or employing
speech technologies are applications in the telephony and call centers,
automatic desktop dictation software, telematic, personal hand-held
communication solutions, Internet voice portals and research and development
markets. Historically, development of speech products in an emerging market has
been affected by declining margins, large memory requirements, non- extendable
technology, operating system platform dependence, lack of integration and
non-recurring engineering dependence. Recently, several forces have driven
market trends toward accelerated demand for speech including technology
convergence (more speech products companies and proliferation of the world wide
web), explosive growth in mobile personal communications and organization
devices, and legislative concerns for consumer safety and handicap access to
technology.
The Company has strategically sought markets for its core technologies
with high margins, broad use, rapid development and market emergence/presence.
Fonix has also strategically avoided markets with low margins which are
commodity driven, subject to continuous price compression and require massive,
costly customer support systems.
The Company's current marketing strategy is governed by the following
general principles:
1. Specific focus on markets where current revenues can be realized
through a market driven approach and away from markets focusing on
continued research and development.
2. Pursuit of customers who enjoy dominant or significant market share in
their respective markets and who
22
<PAGE>
display financial ability and marketing organization to rapidly bring
products to market.
3. Pursuit of integration into customer products where Fonix technology is
directly compatible and can go to market with minimal additional
development engineering.
4. Partner with customers who have existing marketing channels in place
and leverage product sales through those channels.
5. Generally position Fonix as a provider of second tiercustomer support,
providing training and tools for Fonix customers who create excellent
front line support systems for their end-user customers.
Because the Company is pursuing integration into mass market,
industrial, general business and personal electronic products and computing
solutions, lead time to revenue generation is longer than retail, commodity
driven software products. The Company's products sold and integrated into
customer applications are subject to both customer production schedules and
customer success in marketing the products and generating product sales. The
Company's revenues are thus subject to delays and possible cancellation
resulting from customer integration delays.
To bring the Company's proprietary technologies to market, Fonix has
focused marketing and product development into embedded markets and server-based
markets.
Embedded Markets
Increasingly efficient and powerful computing solutions have rapidly
developed new markets by creating smaller, more convenient devices equipped with
personalized functions. These devices include PDAs (personal digital
assistants), cellular phones, web pads, wireless communications devices, and
other consumer electronics. A significant deterrent to full functionality of
powerful yet small computing devices is the current need for a keyboard and/or a
mouse to interface with the device. Recent integration of HWR technology has
helped to increase the demand for natural, intuitive human/computer interactions
with these devices and has helped markets to emerge ready to pay for speech
recognition and synthetic speech in computing solutions. The next step to
greater human/computer interaction is to integrate speech into these products.
Other product developments are driving additional interest in human/computer
technologies including new products (electronic books, wearable computers),
testing of smart appliances and toys (VCRs, answering machines, wireless phones,
climate control systems) and automotive applications (command and control, hands
free cellular phones and voice activated navigation systems).
Historically, micro processors did not contain enough memory or
computing power (MIPS) to operate most ASR and TTS applications. This created a
significant problem for embedded markets. Adding the hardware necessary to boost
memory and computing power would increase the price of devices higher than
consumer markets would tolerate.
Because of proprietary engineering innovations, Fonix ASR and TTS
technologies have memory and power requirements that fall well within tolerances
needed to speech enable applications using existing 16 bit and 32 bit
processors. To capitalize on this distinct competitive advantage, Fonix is
pursuing sales and partnership relationships with companies offering embedded
products for mass consumer markets, industrial applications and business
computing solutions.
Fonix has identified key embedded market segments which it believes
will provide long term, sustainable revenue flow using proprietary ASR, TTS and
HWR technologies and which meet Fonix's general business strategy objectives.
These strategically focused embedded markets include:
1. Chip Manufacturers. Digital signal processor ("DSP") and micro
processor manufacturers are currently highly focused on technology
innovations which will support and drive sales of chips through third
party vendors. Because Fonix ASR and TTS technologies have demonstrated
the ability to operate in these environments, Fonix is pursuing
relationships with these manufacturers to leverage their existing
marketing channels.
2. Design and Development Contractors. Firms designing reference platforms
and real products and developing functions operating on those platforms
through contracts with major mass market product suppliers provide a
strong market for Fonix with channels to major consumer electronics
marketers.
3. Software Developers. Many software developers in multiple markets
provide opportunity for Fonix to enhance
23
<PAGE>
software sales for these companies by enabling their software products
with one or more human/computer interaction technologies, leading to
leveraged product sales and royalty revenue for Fonix.
4. Third Party Product Developers. Many companies are currently seeking
ASR, TTS and HWR technologies to integrate into a host of consumer
electronic devices, commercial applications and business solutions.
Fonix evaluates each prospective opportunity and the tradeoff between
revenue potential and development time required. Primary markets for
these applications are in automotive and aviation telematics,
industrial wearable computers, mobile communications devices and PDA's.
Server-Based Markets
Telephony/call center solutions and shrink-wrap desktop dictation
software sales are two of the most advanced emerging markets for automated
speech. Current industry revenue estimates indicate that customized automated
call centers, virtual operators, packaged call center software, custom vertical
market dictation systems and general desktop dictation systems have led
server-based speech applications into the market. Because speech products have
now reached a point of both acceptable product quality and initial market
acceptance, several additional industries are currently researching and
developing plans for integration of ASR, TTS and HWR. These new product areas
including network systems, telephone company e-mail reader services, software
document readers, Internet navigation and screenless Internet access, web site
text readers, mobile computing solutions and many more.
The Company is addressing this market opportunity from the strengths of
its core technologies. Fonix has released version 1 of its FAAST (Fonix
Accelerated Application Speech Technology) for Servers. FAAST for Servers
provides application developers with a tool enabling rapid development of ASR
and TTS which can be quickly and cleanly ported into their product. FAAST for
Servers is targeted to currently emerging and newly developing markets expected
to utilize speech applications in the near and mid-term future.
In addition, the Company is focused on direct product development in
server-based markets. This focus is employed in three primary areas:
1. Internet Voice Portals. Speech enabled access to the Internet and web
site navigation is a rapidly emerging need. Fonix is developing and
will soon implement products for voice portals to the Internet which
may be purchased for use by portal companies, web sites and content
providers, Internet service providers, and browsers.
2. TTS for Reading Web Sites. Since over 70% of all web content is text,
demand for products allowing web content to be read to the user is
rapidly growing. Fonix has developed a web page reader which can be
added to web sites. Working in concert with established audio players,
this product is targeted toward the largest web content providers
worldwide in media, government, business and other industries.
3. Network Systems Command and Control and E-mail Reader. Fonix provides
both ASR and TTS which can be seamlessly integrated into network
software to speech-enable software applications.
4. Video Captioning. The Company has developed a means to effectively use
ASR to create automatic forced alignment and automatic closed and open
captioning for video aftermarket editing services. Future versions of
this product will include real-time live closed captioning systems
utilizing Fonix continuous ASR. Major video software developers and
marketers and large scale video editing and production facilities are
prime targets for this product.
Fonix Product Development and Delivery Focus
The focus of Fonix management is to transition a technology research
development team focused on invention and proof of concept into a team which
delivers quality products on schedule and within budget, while at the same time
continuing to achieve technology upgrades to maintain distinct competitive
technology advantages.
To accelerate the delivery of Fonix technologies into the market as
bona fide products, Fonix management has reconfigured the R&D-oriented
development organization into a Product Delivery/R&D matrix organization. The
new structure consists of the traditional R&D-oriented organization overlaid by
product teams led by product managers who are marketing-oriented and charged
with direct profit and loss responsibilities. These responsibilities begin with
market
24
<PAGE>
research and with product definition and specification and end with delivery of
quality products which address real needs identified by the marketplace, on
schedule and within budget. As identified by industry experience, this is a
demanding but necessary role, and has been found industry wide to be
indispensable in transforming a company from the R&D phase into the product
delivery phase.
Year 2000 Issue
Many computer systems and software products are coded to accept only two digit
entries in the date code field. These date code fields will need to accept four
digit entries to distinguish 21st century dates from 20th century dates. As a
result, many companies' software and computer systems will need to be upgraded
or replaced in order to comply with such Year 2000 requirements. Fonix is
subject to the risk that problems encountered with Year 2000 issues, either in
its internal systems, technologies and products, or in external systems, could
adversely affect its operations and financial condition.
In the ordinary course of its business, Fonix tests and evaluates its
technologies and software and hardware products. The Company believes that its
technologies and products are Year 2000 compliant, meaning that the use or
occurrence of dates on or after January 1, 2000 will not materially affect the
performance of such technologies or products with respect to four digit date
dependent data or the ability of such products to correctly create, store,
process, and output information related to such data. However, the Company may
learn that certain of its technologies or products do not contain all necessary
software routines and codes necessary for the accurate calculation, display,
storage, and manipulation of data involving dates. In addition, the Company has
warranted or expects to warrant that the use or occurrence of dates on or after
January 1, 2000 will not adversely affect the performance of its technologies or
products with respect to four digit date dependent data or the ability to
create, store, process, and output information related to such data. If the end
users of any of Company's technologies or products experience Year 2000
problems, those persons could assert claims for damages.
Fonix uses third-party equipment and software that the Company believes to be
Year 2000 compliant. The Company has substantially completed a review of key
products provided by outside vendors to determine if those products comply with
Year 2000 requirements and presently believes that all software provided by
third parties that is critical to its business is Year 2000 compliant. The
Company has also completed a review of all internal systems for Year 2000
compliance and presently believes the internal systems are Year 2000 compliant.
If, however, this third-party equipment or software does not operate properly
with regard to the Year 2000 issue, the Company may incur unexpected expenses to
remedy any problems. Such costs may materially adversely affect the Company's
business, operating results, and financial condition. In addition, if the
Company's key systems, or a significant number of its systems, fail as a result
of Year 2000 problems the Company could incur substantial costs and disruption
of its business. The Company may also experience delays in implementing Year
2000 compliant software products. Any of these problems may materially adversely
affect Fonix's business, operating results or financial condition.
In addition, the purchasing patterns of Fonix's licensees, potential licensees,
customers and potential customers may be affected by Year 2000 issues. Many
companies are expending significant resources to correct their current software
systems for Year 2000 compliance. These expenditures may result in reduced funds
available to license the Company's technologies or to purchase other Fonix
products. This may adversely affect the Company's business, operating results,
and financial condition.
Results of Operations
Three months ended September 30, 1999 compared with three months ended September
30, 1998
During the three months ended September 30, 1999, the Company recorded revenues
of $65,707 from the sale of its Interactive Technologies Solutions Group
products, a decrease of $29,793 over the same period in the previous year. The
decrease is due to a reorganization and redirection of the sales and marketing
staff in the 1999 period.
Selling, general and administrative expenses were $2,864,400 and $2,672,252 for
the three months ended September 30, 1999 and 1998, respectively. Salaries,
wages and related costs were $1,949,422 and $988,412 for the three months
25
<PAGE>
ended September 30, 1999 and 1998, respectively, an increase of $961,010. This
increase is attributable to $1,296,600 in additional compensation to two
executive officers and a former executive officer related to the indemnification
of income taxes resulting from the sale of shares beneficially owned by the
three individuals for payment of Company obligations offset in part by
management's cost reduction initiatives implemented in February 1999. Legal and
accounting expenses decreased $85,626. This decrease is attributed primarily to
the costs of legal and accounting services related to the acquisition of
Articulate and Papyrus and the preparation of registration statements in 1998 in
addition to a reduction in legal fees expended for litigation and patent
registration matters. Marketing expenses decreased $37,853 and consulting and
outside services decreased by $239,491. These decreases are attributable to
management's cost reduction initiatives implemented in February 1999. . The
Company incurred product development and research expenses of $1,906,968 during
the three months ended September 30, 1999, a decrease of $2,389,970 over the
same period in the previous year. This decrease was due primarily to
management's cost reduction initiatives implemented in February 1999. The
Company anticipates similar decreases in product development and research costs
as it begins to complete the development of certain TTS products. During the
three months ended September 30, 1999 and 1998, the Company expended a total of
approximately $100,000 and $50,000, respectively, in connection with the
development of the AcuVoice purchased in-process research and development
projects.
Amortization of goodwill and purchased core technologies were $630,609 and
$500,776 for the three months ended September 30, 1999 and 1998, respectively,
representing an increase of $129,833. This increase is primarily attributable to
the amortization of intangible assets acquired in connection with the
acquisitions of Papyrus.
The Company incurred losses from operations of $5,344,189 and $11,202,838 during
the three months ended September 30, 1999 and 1998, respectively. The decrease
in losses from operations is due primarily to management's cost reduction
initiatives implemented in February 1999, and purchased in process research and
development costs incurred in the acquisition of Articulate in 1998. The Company
anticipates that its investment in ongoing scientific product development and
research will continue at decreased levels for the remainder of fiscal 1999,
assuming availability of working capital.
Net other expense was $1,706,155 for the three months ended September 30, 1999,
a decrease of $4,479,083 over the three months ended September 30, 1998. The
decrease was due primarily to costs attributed to the cancellation of common
stock reset provisions that occurred in 1998 and to a reduction in interest
income of $266,043 from certificates of deposit that were converted to cash to
retire a bank line of credit in January 1999, offset in part by an increase in
interest expense of $1,211,511 attributable to the issuance of the Series C
Convertible Debentures issued in January and March 1999.
Nine months ended September 30, 1999 compared with nine months ended September
30, 1998
During the nine months ended September 30, 1999, the Company recorded revenues
of $351,083, a decrease of $2,216,702 over the same period in the previous year.
In the 1998 period, the Company received revenues of $2,368,138 from Siemens as
a non-refundable license fee for which the Company had no further obligation of
any kind. The 1999 revenues are primarily from sales and licensing fees related
to the TTS technologies and products.
Selling, general and administrative expenses were $7,537,577 and $6,112,765 for
the nine months ended September 30, 1999 and 1998, respectively. Salaries, wages
and related costs were $4,090,525 and $2,584,164 for the nine months ended
September 30, 1999 and 1998, respectively, an increase of $1,506,361. This
increase is attributable to $1,296,600 in expenses related to the
indemnification of income tax liabilities resulting from the sale of shares
beneficially owned by two executive officers and one former executive officer
for payment of Company obligations and to management's redirection of labor
resources from core development and research activities to selling, business
development and marketing activities, offset in part by management's cost
reduction initiatives implemented in February 1999. Additionally, legal and
accounting expenses increased $207,505, the increase is attributed primarily to
the costs of services related to the sale of the HSG assets to L&H and to the
costs of securities filings. Further, marketing expenses decreased $20,837 and
consulting and outside services decreased by $98,178. These decreases are
attributable to management's cost reduction initiatives implemented in February
1999.
26
<PAGE>
The Company incurred product development and research expenses of $6,278,318
during the nine months ended September 30, 1999, a decrease of $3,680,115 over
the same period in the previous year. This decrease was due primarily to
management's cost reduction initiatives implemented in February 1999. The
Company anticipates similar decreases in product development and research costs
as it begins to complete the development of certain TTS products. During the
nine months ended September 30, 1999 and 1998, the Company expended a total of
approximately $250,000 and $80,000, respectively, in connection with the
development of the AcuVoice purchased in-process R&D projects. The Company
anticipates that its investment in ongoing product development and research will
continue at decreased levels for the remainder of 1999 and 2000, assuming
availability of working capital.
Amortization of goodwill and purchased core technologies was $1,962,443 and
$1,100,336 for the nine months ended September 30, 1999 and 1998, respectively,
representing an increase of $862,107. This increase is primarily attributable to
the amortization of intangible assets acquired in connection with the
acquisitions of AcuVoice and Papyrus.
Net other expense was $4,422,997 for the nine months ended September 30, 1999, a
decrease of $1,793,260 over the nine months ended September 30, 1998. This
decrease was due primarily to $6,111,577 in costs attributed to the cancellation
of common stock reset provisions that occurred in 1998 and to a reduction in
interest income of $809,371 from certificates of deposit that were converted to
cash to retire a bank line of credit in January 1999, offset in part by an
increase in interest expense of $3,354,006 attributable to the Series C 5%
convertible debentures issued in January and March 1999.
In-Process Research and Development
At the date of acquisition of AcuVoice, management estimated that the acquired
in-process research and development projects of AcuVoice were approximately 75
percent complete and that an additional $1.0 million would be required to
develop these projects to commercial viability. Additionally, management
anticipated release dates of the fourth quarter of 1999 for the AcuVoice
projects. As of September 30, 1999, the Company has expended a total of
approximately $380,000 in connection with the AcuVoice acquired in-process
research and development projects, and management estimates that a total of
approximately $620,000 will be required to complete the AcuVoice projects.
Management also estimates that the AcuVoice projects are 85 percent complete as
of September 30, 1999, and that the release dates will be in the second quarter
of 2000.
Liquidity and Capital Resources
The Company must raise additional funds to be able to satisfy its cash
requirements during the next 12 months. The research and development, corporate
operations and marketing expenses will continue to require additional capital.
Because the Company presently has only limited revenue from operations, the
Company intends to continue to rely primarily on financing through the sale of
its equity and debt securities or sales of existing technologies or businesses
to satisfy future capital requirements until such time as the Company is able to
enter into additional third-party licensing or co-development arrangements such
that it will be able to finance ongoing operations out of license, royalty and
sales revenue. There can be no assurance that the Company will be able to enter
into such agreements. Furthermore, the issuance of equity securities or other
securities which are or may become convertible into equity securities of the
Company in connection with such financing would result in dilution to the
stockholders of the Company which could be substantial.
The Company had negative working capital of $4,400,201 at September 30,
1999 compared to negative working capital of $14,678,975 at December 31, 1998.
The current ratio was 0.35:1 at September 30, 1999 compared to 0.59:1 at
December 31, 1998. Current assets decreased by $18,277,855 to $2,410,215 from
December 31, 1998 to September 30, 1999. Current liabilities decreased by
$28,506,629 to $6,810,416 during the same period. The increase in working
capital from December 31, 1998 to September 30, 1999, was primarily attributable
to decreases in accounts and notes payable and notes payable to related parties,
offset in part by increases in accrued liabilities, income taxes payable and
decreases in cash and notes receivable. Total assets were $22,398,084 at
September 30,1999 compared to $61,912,791 at December 31, 1998.
27
<PAGE>
Delisting of the Company's Common Stock by Nasdaq
Until recently, the Company's Class A common stock traded on the Nasdaq
SmallCap Market which requires, for continued listing, a minimum bid price of at
least $1.00 per share. At June 29, 1999, the Company's Class A common stock had
traded below $1.00 for more than 30 consecutive trading days. On June 29, 1999,
the Company received a letter from Nasdaq indicating that unless the minimum bid
price for the Company's Class A common stock returned to at least $1.00 per
share for at least 10 consecutive trading days prior to September 29, 1999, the
Company's shares would be delisted from the Nasdaq SmallCap Market on October 1,
1999. The Company appealed the Nasdaq notice and a hearing was held on October
28, 1999.
On December 3, 1999, the Company received notice that its stock had
been delisted from the Nasdaq SmallCap Market as of December 3, 1999, in part
because the stock price had been below $1.00 per share since approximately March
1999. The Company is currently evaluating its options, including the possibility
of appealing the delisting decision. However, the Company's Class A common stock
is currently trading on the OTC Bulletin Board.
The result of delisting from the Nasdaq SmallCap Market could be a
reduction in the liquidity of any investment in the Company's Class A common
stock, even if the Company's shares continue to trade on the OTC Bulletin Board.
Further, delisting could reduce the ability of holders of the Company's Class A
common stock to purchase or sell shares as quickly and as inexpensively as they
have done historically.
The delisting of the Company's common stock from the Nasdaq SmallCap
Market was an event of default under the terms of the Debentures and the
Repurchase Rights. Upon the occurrence of this event of default, the unpaid
principal amount of the Debentures, together with accrued interest thereon, was
immediately due and payable. However, the holders of the Debentures and the
Repurchase Rights have waived this event of default.
Sale of the HealthCare Solutions Group
In September 1999, the Company completed the sale of the operations and
a significant portion of the assets (the "Sale") of its HealthCare Solutions
Group (the "HSG") to Lernout & Hauspie Speech Products N.V. ("L&H"), an
unrelated third party, for up to $28,000,000. Of this sales price, $21,500,000,
less certain credits of $194,018, was paid at closing, $2,500,000 is being held
in an 18 month escrow account in connection with the representations and
warranties made by the Company at the time of the Sale. Any remaining amount up
to $4,000,000 is an earnout contingent on the performance of the HSG over the
next two years. The Company will not record the contingent earnout, if any,
until successful completion of the earnout period. The proceeds from the Sale
were used to reduce a significant portion of the Company's liabilities and to
provide working capital for the Company's marketing and distribution
opportunities for its Interactive Technology Solutions Group. The assets sold
include inventory, property and equipment, certain prepaid expenses, purchased
core technology and other assets of HSG. Additionally, L&H assumed the capital
and operating lease obligations related to the HSG and the obligations related
to certain of the Company's deferred revenues.
Notes Payable
After the Papyrus acquisition closed in October 1998, the Company
investigated some of the representations and warranties made by Papyrus to
induce the Company to acquire the Papyrus companies. The Company determined that
certain of the representations made by Papyrus and its executive officers
appeared to be inaccurate. On February 26, 1999, the Company filed an action
against the former stockholders of Papyrus alleging misrepresentation and breach
of contract. In March and April 1999, five of the former stockholders of Papyrus
filed actions against the Company alleging default under the terms of the
promissory notes issued to them in connection with the Papyrus acquisition and
certain other claims. Subsequently, the Company entered into agreements with the
five former Papyrus stockholders for dismissal of the actions and cancellation
of the promissory notes upon payment to the former stockholders of $1,217,384
(the "Settlement Payment") and return of 970,586 shares of restricted common
stock previously issued to the five former stockholders in connection with the
acquisition of Papyrus. The Company paid the Settlement Payment in September
1999 and the lawsuits described above have been dismissed. The 970,586 shares
were effectively canceled in September 1999 in connection with the Settlement
Payment. The original fair market value of $1,000,917 associated with the
canceled shares was reflected as a reduction to goodwill associated with the
purchase of Papyrus Associates, Inc. As of September 30, 1999, the Company had
unsecured notes payable to former Papyrus stockholders in the
28
<PAGE>
aggregate amount of $77,625, which notes were issued in connection with the
acquisition of Papyrus. The holders of these notes have not made demand for
payment.
During the nine months ended September 30, 1999, the Company paid, or
otherwise reduced through agreement notes payable to various related parties
totaling $8,818,355, plus accrued interest. Additionally, the Company paid other
notes payable to unrelated parties aggregating $560,000 plus accrued interest.
Additionally, a revolving note payable in the amount of $50,000 was paid by a
former employee and is included as an account payable. A revolving note payable
in the amount of $19,988,193 at December 31, 1998, plus accrued interest, was
paid in full in January 1999 with the proceeds from a certificate of deposit
that secured the note and $22,667 in cash.
In September 1999, the Company negotiated reductions of $221,376 in
amounts due various trade vendors. Additionally, the Company negotiated
reductions of $150,685 in accrued interest owed to certain note holders. These
amounts have been accounted for as extraordinary items in the 1999 condensed
consolidated statements of operations.
December 1998 Equity Offering
In connection with the Company's Equity Offering in December 1998, the
holder of the 1,801,802 Class A common shares and the Repricing Rights may, upon
the occurrence of certain events, require the Company to repurchase all or a
portion of the holder's Class A common shares or repricing rights received in
the Equity Offering, as follows:
o For each Class A common share with a repricing right, the
greater of $1.3875 or the sum of $1.11 plus the product of the
Repricing Rate multiplied by the last reported sale price.
o For each Repricing Right without the associated Class A common
share, the product of the Repricing Rate multiplied by the
last reported sale price.
o For each Class A common share without the associated
Repricing Right, $1.3875.
For each of the above examples, the Repricing Rate is determined by
calculating the following fraction:
(Repricing Price - Market Price)
--------------------------------
Market Price
As of December 13, 1999, the Repricing Price was $1.4319, and the market price
was $0.30.
The events which trigger the Repurchase Rights include a failure by the
Company to have a registration statement registering the Class A common shares
and the shares underlying the Repricing Rights in the Equity Offering declared
effective by June 19, 1999, or the delisting of the Class A common stock from
the Nasdaq SmallCap Market. Because both of these events have occurred, the
investor in the Equity Offering had the right to exercise the repurchase option.
However, the Equity Offering investor waived its right to exercise the
repurchase option as a result of the delisting of the Class A common stock from
the Nasdaq SmallCap Market and deferred until March 1, 2000, its right to
require repurchase as a result of the Company's failure to register the shares
underlying the Repurchase Rights and Class A common stock. If such shares are
not registered before March 1, 2000, the Equity Offering investor may exercise
the Repurchase Rights. Presently, the Company does not have sufficient cash or
other liquid assets to pay the amount which would be due if the holder of the
Class A common shares and the Repricing Rights exercised its Repurchase Rights.
Series C 5% convertible debentures
On January 29, 1999, the Company entered into a securities purchase
agreement with four investors pursuant to which the Company sold its Series C 5%
convertible debentures in the aggregate principal amount of $4,000,000. The
outstanding principal amount of the Debentures is convertible at any time at the
option of the holders into shares of the Company's common stock at a conversion
price equal to the lesser of (1) $1.25 or (2) 80% of the average of the closing
bid price of the Company's common stock for the five trading days immediately
preceding the conversion date.
29
<PAGE>
However, in the event that the Company fails to file and have declared effective
the registration statement registering the shares underlying the Debentures, the
holders of the Debentures may elect penalty provisions to (a) reduce the
conversion price by 2.5% per month until the registration statement is declared
effective, or (b) receive 2.5% of the outstanding principal amount of Debentures
per month, in cash. To date, the Company has not filed the registration
statement or had it declared effective as required. However, all holders waived
the penalty provisions through June 30, 1999. Additionally, some holders of the
Debentures agreed to a partial waiver of their penalty provisions through
September 30, 1999. The holders of the Debentures have agreed to waive the
penalty provisions, contingent on the registration statement being declared
effective by February 29, 2000. In the event that the registration statement is
not declared effective by that date, the penalty provisions automatically apply,
retroactive to October 1, 1999.
The outstanding principal amount of the Debentures bears interest at a
rate of 5%, payable on March 31, June 30, September 30, and December 31, and on
each conversion date, of each year during the term of the Debentures. In
addition, the interest on the outstanding principal amount of the Debentures
may, at the Company's option, be paid in shares of the Company's Class A common
stock calculated based upon the Debenture Conversion Price on the date such
interest becomes due. The Company has not paid interest on the Debentures at any
time since they were issued. Under the terms of the Debentures, the investors
could charge penalties for such failure. However, the investors have waived all
such penalties accruing prior to October 1, 1999.
The Company recorded $687,500 as interest expense upon the issuance of
the Debentures in connection with this beneficial conversion feature. The
Company also issued 400,000 warrants to purchase an equal number of the
Company's common shares at a strike price of $1.25 per share in connection with
this financing. The warrants are exercisable for a period of three years from
the date of grant. The estimated fair value of the warrants of $192,000, as
computed under the Black-Scholes pricing model, was recorded as interest expense
upon the issuance of the Debentures. On March 3, 1999, the Company executed a
supplemental agreement pursuant to which the Company agreed to sell another
$2,500,000 principal amount of the Debentures on the same terms and conditions
as the January 29, 1999 agreement, except no additional warrants were issued.
The Company recorded $1,062,500 as interest expense upon the issuance of the
supplemental Debentures in connection with the beneficial conversion feature.
The obligations of the Company for repayment of the Debentures, as well as its
obligation to register the common stock underlying the potential conversion of
the Debentures and the exercise of the warrants issued in these transactions,
were personally guaranteed by two officers and directors and a former officer
and director of the Company (the "Guarantors"). In connection with the March 3,
1999 funding, the Company agreed to grant a lien on the patent covering the
Company's ASR technologies as collateral for repayment of the Debentures.
However, to date no lien on the patent has been granted. The Guarantors
guaranteed the obligations of the Company under the Debentures and pledged
6,000,000 shares of common stock of the Company beneficially owned by them as
collateral security for their obligations under their guarantees.
Subsequent to the March 3, 1999 funding, the holders of the Debentures
notified the Company and the Guarantors that the Guarantors were in default
under the terms of the stock pledge agreement and that the holders intended to
exercise their rights to sell some or all of the pledged shares of the
Guarantors. The holders of the Debentures have subsequently informed the Company
that they have sold the 6,000,000 shares pledged by the Guarantors and that
proceeds from the sale of the pledged shares aggregated $3,278,893. Of this
total, $406,250 was allocated to penalties attributable to default provisions of
the stock pledge agreement and recorded as interest expense and $343,750 related
to penalty provisions of the Series D preferred stock and recorded as preferred
stock dividends. Both of these amounts were recorded by the Company during the
three months ended September 30, 1999. The remaining $2,528,893 of the proceeds
was applied as a reduction of the principal balance of the Debentures as of
September 30, 1999. Under its indemnity agreement with the Guarantors, the
Company will issue 6,000,000 replacement shares to the Guarantors for the shares
sold by the holders and reimburse the Guarantors for any costs incurred as a
result of the holders' sales of the Guarantors' shares. Accordingly, the Company
recorded an expense of $1,296,600 during the nine months ended September 30,
1999.
Guarantors
In addition to guaranteeing obligations relating to the Debentures, the
Guarantors guaranteed certain other obligations of the Company. As security for
some of the guarantees, the Guarantors pledged shares of the Company's
30
<PAGE>
common stock beneficially owned by them. In March 1999, 143,230 of the shares
previously pledged by the Guarantors to a bank were sold by the bank and the
proceeds were used to pay Company credit card balances and the related accrued
interest in full totaling $244,824. In May 1999, 100,000 of the shares
previously pledged by the Guarantors to another creditor of the Company were
sold by the creditor and the proceeds, totaling $72,335, were used to pay
amounts owed by the Company. In September 1999, the Company paid a note payable
to an unrelated third party in the amount of $560,000 that had previously been
guaranteed by the Guarantors. As of September 30, 1999, no guarantees remain
outstanding.
Series D and Series E preferred stock
During the nine months ended September 30, 1999, 131,667 shares of
Series D preferred stock and 135,072 shares of Series E preferred stock,
together with related dividends on each, were converted into 8,468,129 shares
and 5,729,156 shares, respectively, of the Company's Class A common stock. After
the above conversions, 876,667 shares of Series D preferred stock remained
outstanding as of September 30, 1999. Subsequent to September 30, 1999, a total
of 494,944 shares of Series D preferred stock, together with related dividends,
were converted into 34,591,946 shares of the Company's Class A common stock. As
of December 13, 1999, 381,723 shares of Series D preferred stock remain
outstanding.
Class A common stock, stock options, and warrants
On June 2, 1999, the Company issued 200,000 shares of common stock
(having a market value of $100,000 on that date) to an unrelated individual in
payment for consulting services rendered.
During the nine months ended September 30, 1999, the Company granted
754,500 stock options to employees at exercise prices ranging from $0.59 to
$1.78 per share. Additionally, 9,500 stock options were granted to two
consultants for services provided to the Company. The fair market value of the
consultant options was $1.30 per share, or $12,540 in total, using the
Black-Scholes pricing model and was charged to product development and research
expense. The term of all options granted during this nine month period is ten
years from the date of grant. Of the stock options issued, 726,334 vested
immediately, 18,834 vest six months after issuance and 18,832 vest one year
after issuance. As of September 30, 1999, the Company had a total of 15,536,582
options outstanding.
During the nine months ended September 30, 1999, the Company granted
warrants to L&H in connection with loans made to the Company in April and May
1999 totaling $6,000,000. These warrants allow L&H to purchase 850,000 shares of
Class A common stock of the Company at exercise prices ranging from $0.60 to
$0.70 per share. Of these warrants, 250,000 expired October 18, 1999, without
being exercised. The remaining 600,000 warrants expire May 17, 2001.
On February 11, 1998, the Company entered into a First Statement of
Work and License Agreement with Siemens under which the Company and Siemens are
jointly pursuing the development of Siemens' integrated circuits incorporating
ASR and other related technologies for use in certain telecommunications
applications. In connection with the license agreement Siemens purchased
warrants to acquire 1,000,000 shares of restricted common stock at an average
exercise price of $20 per share with expiration dates ranging from December 31,
1998 to December 31, 1999. As of September 30, 1999, 800,000 of the warrants
originally issued had expired and 200,000 of the warrants remain outstanding at
an average exercise price of $30 per share.
As of September 30, 1999, the Company had a total of 2,475,000 warrants
outstanding.
The Company presently has no plans to purchase any new research and
development assets or office facilities.
Special Note Regarding Forward-Looking Statements
Certain statements contained herein under, "Management's Discussion and Analysis
of Financial Condition and Results of Operations" and "Outlook," including
statements concerning (i) the Company's strategy, (ii) the Company's expansion
plans, (iii) the market for and potential applications of the Company's
technologies, (iv) the results of product
31
<PAGE>
development and research efforts, and (v) the growth of the Company's business
contain certain forward-looking statements concerning the Company's operations,
economic performance and financial condition. Because such statements involve
risks and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Factors that could
cause such differences include, but are not necessarily limited to, those
discussed in the Company's Annual Report on Form 10-K (as amended) for the year
ended December 31, 1998.
32
<PAGE>
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
Clarke - On August 28, 1998, John R. Clarke and Perpetual Growth Fund, a company
Clarke's spouse purportedly owns, commenced an action against the Company in
federal court for the Southern District of New York. Clarke and Perpetual Growth
asserted claims for breach of contract relating to certain financing the Company
received during 1998. Specifically, Clarke and Perpetual Growth alleged that
they entered into a contract with the Company under which the Company agreed to
pay them a commission of five percent of all financing provided to Fonix by
Southridge Capital Management or its affiliates. Clarke and Perpetual claim that
they are entitled to commissions with respect to approximately $3,000,000 of
equity financing to the Company in July and August 1998, and the Company's
offerings of Series D and Series E preferred stock, totaling together
$12,000,000, in August and September 1998.
The Company believes that the Clarke lawsuit is without merit and filed a motion
to dismiss based upon the court's lack of personal jurisdiction over the
Company. The court granted the Company's motion to dismiss. Clarke and Perpetual
Growth have appealed the dismissal, and such appeal has been denied. The Company
has filed a suit against Clarke and Perpetual Growth in federal court for the
Central District of Utah seeking a declaratory judgment that it does not owe any
money to Clarke and Perpetual Growth. Now that the action in New York has been
dismissed, the Company intends to vigorously pursue the Utah action.
Papyrus - After the Papyrus acquisition closed in October 1998, the Company
investigated some of the representations and warranties made by Papyrus to
induce the Company to acquire Papyrus. The Company determined that certain of
the representations made by Papyrus and their executive officers appeared to be
inaccurate. On February 26, 1999, the Company filed an action against Papyrus in
the United States District Court for the District of Utah, Central Division,
wherein the Company alleged claims for misrepresentation, negligent
misrepresentation, breach of contract, breach of the implied covenant of good
faith and fair dealing and rescission. On March 11, 1999, three of the former
shareholders of Papyrus filed an action against the Company in the United States
District Court for the District of Massachusetts, alleging a default under the
terms of the promissory notes issued to them in connection with the Papyrus
acquisition. On April 2, 1999, the three former Papyrus shareholders filed an
amended complaint against the Company seeking additional remedies including
violation of Massachusetts unfair and deceptive acts and practices statutes and
copyright infringement. On April 8, 1999, a fourth former Papyrus shareholder
filed an action against the Company alleging a default under the terms of the
promissory notes issued to him in connection with the Papyrus acquisition and
seeking additional remedies including violation of Massachusetts unfair and
deceptive acts and practices statutes and copyright infringement. On April 13,
1999, a fifth former Papyrus shareholder filed a similar action in
Massachusetts. Subsequently, the Company has entered into agreements with the
five former Papyrus shareholders for dismissal of the actions and cancellation
of the promissory notes upon payment to the former shareholders of $1,188,909
(the "Settlement Payment") and return for cancellation by the Company of 970,586
shares of restricted common stock issued to the five former shareholders in
connection with the acquisition. The Company agreed to pay the Settlement
Payment on or before August 31, 1999 or, if the definitive proxy soliciting
consents from the shareholders of the Company is effective prior to August 31,
1999, upon the closing of the sale of the HSG assets or the Company and the five
former Papyrus shareholders are free to pursue their respective claims.
OGI - On July 28, 1999, Oregon Graduate Institute ("OGI") filed a notice of
default, demand for mediation and demand for arbitration with the American
Arbitration Association. In its demand, OGI asserted that Fonix was in default
under three separate agreements between the Company and OGI in the total amount
of $175,000.00. On or about September 23, 1999, the Company responded to OGI's
demand and denied the existence of a default under the three agreements
identified by OGI. Moreover, the Company asserted a counterclaim against OGI in
an amount not less than $250,000.00. The Company anticipates that the American
Arbitration Association will conduct a scheduling conference within the next
twenty days of which dates for the proceeding, including the arbitration
hearing, will be set.
In addition to the above, the Company is involved in various lawsuits, claims
and actions arising in the ordinary course of business. In the opinion of
management, after consultation with legal counsel, the ultimate disposition of
these matters will not materially affect the consolidated financial position or
results of operations of the Company.
33
<PAGE>
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
Fonix Corporation
Date: December 29, 1999 /s/ Douglas L. Rex
--------------------------------- ----------------------------------------
Douglas L. Rex, Chief Financial Officer
34
